

**THE UNIVERSITY OF ALABAMA AT BIRMINGHAM
SCHOOL OF MEDICINE
FACULTY CURRICULUM VITAE**

Date: July 30, 2007

PERSONAL INFORMATION:

Name: Kenneth G. Saag, M.D., M.Sc.



RANK/TITLE Professor
Department of Medicine
Business Address: Division of Clinical Immunology and Rheumatology
The University of Alabama at Birmingham
510 20th Street South
FOT 820
Birmingham, AL 35294-3408
Phone: (205) 934-0893, Fax (205) 975-6859

HOSPITAL AND OTHER (NON-ACADEMIC) APPOINTMENTS:

7/89-7/90	Staff Physician	Evanston Hospital, Evanston, IL.
12/92-8/98	Staff Physician	University of Iowa Hospitals and Clinics, Iowa City
12/92-8/98	Staff Physician	VA Medical Center, Iowa City, Iowa
9/98-present	Staff Physician	University of Alabama at Birmingham

PROFESSIONAL CONSULTANTSHIPS:

EDUCATION:

Institution	Degree	Year
University of Michigan, Ann Arbor, Michigan	B.S.E.	9/78-6/82
Northwestern University, Chicago, Illinois	M.D.	9/82-6/86
Department of Preventive Medicine and Environmental Health, University of Iowa, Iowa City, Iowa	M.Sc., Epidemiology	9/92-6/93

LICENSURE:

<u>State</u>	<u>Date</u>	<u>Perm./Temp.</u>	<u>Number</u>	<u>Renewal Date</u>
Alabama	8/26/98	Perm.	_____	12/31/05
Iowa	1990	Perm.	_____	Inactive
Illinois	1987	Perm.	_____	Inactive

BOARD CERTIFICATION:

	<u>Date</u>	<u>Number</u>
National Board of Medical Examiners	1987	_____
American Board of Internal Medicine	9/89	_____
ABIM, Subspecialty Board of Rheumatology	11/02	_____

POSTDOCTORAL TRAINING:

Year	Position	Institution
1986-89	Resident, Internal Medicine	Northwestern University, Evanston Hospital, Evanston, Illinois
1989-90	Chief Resident, Internal Medicine	Northwestern University, Evanston Hospital, Evanston, Illinois
1990-93	Fellow in Rheumatology	University of Iowa Hospitals and Clinics, Iowa City

ACADEMIC APPOINTMENTS:

Year	Rank/Title	Institution
7/89	Instructor in Medicine	Northwestern University
7/93-7/94	Associate	Department of Internal Medicine, University of Iowa College of Medicine
7/94-7/98	Assistant Professor	Department of Internal Medicine, University of Iowa College of Medicine
11/97-7/98	Assistant Professor (Secondary appointment)	Department of Preventive Medicine and Environmental Health University of Iowa College of Medicine
9/98-9/06	Associate Professor (Secondary appointment)	University of Iowa College of Medicine University of Alabama at Birmingham Department of Medicine Division of Clinical Immunology/Rheumatology
	Scientist	Department of Epidemiology, School of Public Health
	Scientist and Group Leader, Clinical Research Committee	Arthritis and Musculoskeletal Center Center for Metabolic Bone Disease
	Scientist	Center for Outcomes and Effectiveness Research and Education
	Scientist	Center for Nursing Research
	Scholar	Lister Hill Center for Health Policy
	Scientist	Center for Aging
1/01-Present	Director	Center for Education and Research on Therapeutics (CERTs) of Musculoskeletal Disorders

10/06-Present	Professor (Secondary appointment)	University of Alabama at Birmingham Department of Medicine Division of Clinical Immunology/Rheumatology Department of Epidemiology, School of Public Health
---------------	--	--

AWARDS/HONORS:

<u>Year</u>	<u>Honor</u>
1981	Tau Beta Pi Engineering Honor Society
1987	Outstanding Intern of the Year
1989	Finalist, Associates Clinical Poster Competition, 70 th Annual Session, American College of Physicians
1998	Training Grant Program in Epidemiology and Biometry of Aging
1998	AOA Medical Students' Nominee for honorary AOA membership
1996-	Listed in <i>Best Doctors</i>
2001, 02	Rheumatology Division Teacher of the Year
2005	Max Cooper Research Award

PROFESSIONAL SOCIETIES:

<u>Year</u>	<u>Organization</u>
	Fellow, American College of Physicians
	Fellow, American College of Rheumatology
	Association for Health Services Research
	American Federation of Clinical Research
	American Society of Bone and Mineral Research
	International Society of Clinical Densitometry
1996	Central Society for Clinical Research

COUNCILS AND COMMITTEES:

<u>Year</u>	<u>Committee</u>
1994	Participant, Outcome Measurements in Rheumatology Conference (OMERACT II)
1995	Residency Selection Committee, University of Iowa
1995	High vs. Low Dose D-Penicillamine in Systemic Sclerosis Data and Safety Monitoring Committee
1995	National Arthritis Care Algorithm Steering Committee
1996	Clinical Research Committee, Department of Internal Medicine
1997	NIAMS Working Group on Epidemiology, Education, and Health Services Research
1997	Ad hoc Reviewer, University of Pittsburgh, Scleroderma SCOR Grant
1998	Ad hoc Reviewer, NIH General Medicine A-1 Study Section
1998	NIH NIAMS Multipurpose Arthritis and Musculoskeletal Diseases Centers (MAMDC), Special Emphasis Panel
1998	American College of Rheumatology (ACR) Atypical Connective Tissue Diseases Classification Criteria Committee
1998-01	ACR Professional Meetings Committee
1998	ACR ad hoc committee to revise Guidelines for Glucocorticoid-Induced Osteoporosis
1998-02	Institute of Medicine- Committee on Identifying Effective Treatment for Gulf War Veteran's Health Problems

1999 Ad hoc Reviewer, Canadian Arthritis Society
2000 NIH NIAMS Multidisciplinary Clinical Research Centers (MCRC), Special Emphasis Panel
2001 Residency Selection Committee, University of Alabama at Birmingham
2001 Chairman, ACR Summer Rheumatology Meeting Planning Committee
2001 Ad hoc Reviewer, NIH Epidemiology Disease Control 3
2001-03 Review Committee, Clinical Outcomes and Therapeutics Study Section, Arthritis Foundation
2001 NIH NIAMS Multidisciplinary Clinical Research Centers (MCRC), Special Emphasis Panel
2002 ACR Educational Products Committee
2002- ACR Representative to Outcomes Measures in Rheumatology (OMERACT) conference, Brisbane, Australia
2002 ACR Academic Rheumatology Workforce Ad Hoc Committee
2002 AMA Osteoarthritis Performance Measures Physicians Workgroup
2003 National Center for Quality Assurance Musculoskeletal Workgroup
2003 Co-chair, Review Committee, Clinical Outcomes and Therapeutics Study Section, Arthritis Foundation
2004, 05 Chair, Review Committee, Clinical Outcomes and Therapeutics Study Section, Arthritis Foundation
2005- Member, UAB Conflict of Interest Review Board (CIRB)
2005 Member, American Pain Society Low Back Pain Guidelines Committee
2005 Member, Technical Expert Panel, Oregon Evidence-based Practice Center, Analgesics Guidelines Committee
2005- Board of Directors, American Gout Society
2005- Member, Global Longitudinal Osteoporosis Study of Women (GLOW) Steering Committee
2006 Co-chair, AMA Consortium on Osteoporosis Quality Measures
2006- Member, Data Safety Monitoring Board for _____
2006 Member, Steering Committee, University of California, San Francisco, Multidisciplinary Clinical Research Center
2006 Member, FDA Arthritis Drugs Advisory Committee
2007 Member, Southern Society for Clinical Investigation
2007 Associate Director, UAB Center for Metabolic Bone Disease (CMBD) NIH T32 Institutional Training Grant entitled "Comprehensive Training Grant in Bone Biology and Disease"
2007 Chair, Osteoporosis Abstract Selection Committee, ACR

EDITORIAL BOARD MEMBERSHIPS:

<u>Year</u>	<u>Activity</u>
	Reviewer: <i>Annals of Internal Medicine, Annals of the Rheumatic Diseases, Arthritis and Rheumatism, Archives of Internal Medicine, Arthritis Research and Therapies, Journal of Clinical of Clinical Densitometry, Journal of Rheumatology, Journal of Rheumatology, Medical Care, Rheumatology, Scandinavian Journal of Rheumatology, Spine, Musculoskeletal Medicine, The American Journal of Epidemiology, The American Journal of Medicine, UpToDate</i>
1997-present	Editorial Board, <i>Arthritis Care and Research</i>
1998-2001	Editorial Board, <i>Rheumatoid Arthritis Index & Review</i>
2001-2001	Osteoporosis Section Editor, <i>On-line Journal Club</i>
2001, 02	Osteoporosis Section Editor, <i>Current Opinions in Rheumatology</i>
2003-present	Osteoporosis Section Editor, <i>Current Rheumatology Reports</i>
2007-present	Outcomes Section Associate Editor, <i>Arthritis, Research & Therapy</i>

MAJOR RESEARCH INTERESTS:

Dr. Saag's current research focuses on the epidemiology of osteoporosis and rheumatoid arthritis as well as methods to translate evidence into practice for both arthritis and osteoporosis.

TEACHING EXPERIENCE:

1999 Classroom, Seminar, or Teaching Laboratory:

General Clinical Research Center Conferences

<u>Year</u>	<u>Lecture Title</u>
1994	"Rheumatoid Arthritis Interstitial Lung Disease and The University of Iowa Rheumatoid Arthritis Cohort."
1996	"The Role of Cigarette Smoking in Rheumatoid Arthritis"
1997	"Pharmaco-economic Evaluations of Low Dose Long-term Corticosteroids"

Correlative Pathology (M2)

<u>Year</u>	<u>Lecture Title</u>
1999-	"Rheumatoid Arthritis"

Introduction to Clinical Medicine (M2)

<u>Year</u>	<u>Lecture Title</u>
1999-	"Musculoskeletal Advanced Physical Examination"

Clinical Research Training Program and Language of Clinical Research Course

<u>Year</u>	<u>Lecture Titles</u>
1999-	"Grant Writing", "Critical Review of the Literature", "Evidenced-based Medicine"

Molecular Basis of Disease (Pathology 701)

<u>Year</u>	<u>Lecture Title</u>
1999-	"Rheumatoid Arthritis Clinical Aspects"

Molecular Physiology and Medicine: Fundamental Insights into Common Diseases (Physiology 750)

<u>Year</u>	<u>Lecture Title</u>
2000	"Fibromyalgia"

UAB Grand Rounds and Clinical Conferences

<u>Year</u>	
1999	Department of Dermatology, “Glucocorticoid-Induced Osteoporosis”
1999	Department of Medicine, Division of Gastroenterology, “Glucocorticoid-Induced Osteoporosis”
2000	Department of Medicine, Division of Endocrinology, “Glucocorticoid-Induced Osteoporosis”
2000	Department of Medicine, Division of Pulmonary and Critical Medicine, “Glucocorticoid-Induced Osteoporosis”
2000	Department of Radiology “Arthritis Overview for Radiologists”
2000	Department of Pediatrics, Division of Gastroenterology, “Glucocorticoid-Induced Osteoporosis”
2000	Department of Physical Medicine and Rehabilitation, “Glucocorticoid-Induced Osteoporosis”
2003	Department of Medicine “Glucocorticoids in Chronic Diseases—Bones of Contention”
2004	Department of Dermatology, “Osteoporosis Update 2004”
2005	Department of Pediatrics, Division of Nephrology, “Glucocorticoid-Induced Osteoporosis”
2006	Department of Medicine, Division of Endocrinology, “Glucocorticoid-and other Non-menopausal Causes of Osteoporosis”

Epidemiology and Outcomes Seminars and Courses

<u>Year</u>	<u>Lecture Title</u>
1994	“Therapeutic Misadventures in Rheumatoid Arthritis”
1995	“The Effects of Smoking on Rheumatoid Arthritis”
1995	“The Epidemiology of Rheumatoid Arthritis”
1996	“Outcome Measures in Rheumatology”
1997	Introduction to Clinical Epidemiology (63:171:024) – “Health Related Quality of Life”, Decision Analysis”, “Cost Effectiveness Analysis”
1998	Intervention and Clinical Trials (63:289) “Study Design Issues in Arthritis and Osteoporosis Clinical Trials”
2000	UAB Center for Outcomes Effectiveness Research and Educations (COERE) quarterly seminars “Glucocorticoids in Chronic Disease: Patient Preferences and Provider Practices”
2002	Survey Research Methods (HB 714): “Patient Preferences”
2003-	Epidemiology of Chronic Diseases (EPI 602): “Musculoskeletal Disorder”

Morbidity and Mortality Conference

<u>Year</u>	<u>Lecture Title</u>
1999	Discussant: “A Case of Reactive Arthritis”

Physical Medicine and Rehabilitation Residency Program Noon Lecture Series

<u>Year</u>	<u>Lecture Title</u>
2000	“Rheumatoid Arthritis, Crystalline Arthritis, and Septic Arthritis”

1999. Clinical Teaching (in ward, clinic, or operating room):

<u>Year</u>	<u>Where Teaching Occurred</u>	<u>Weeks/Yr</u>	<u>Hours/Wk</u>
1996-98	Univ. of Iowa CRC Rotation Mentor	12	2

1997-98	Univ. of Iowa M2 Physical Examination Mentor	3	12
1998	Resident's Rheumatology Rotation Preceptor Talks: "Rheumatoid Arthritis"	12	1
1998	Inpatient Consultation Service	6	15
1999	UAB Minority Medical Education Program Mentor	6	4

MAJOR LECTURES AND VISITING PROFESSORSHIPS (PAST 8 YEARS)

1998	Northwestern University, Invited speaker, "Corticosteroids in RA".
1998	Washington University Rheumatology Grand Rounds, "Corticosteroids in Chronic Disease"
1998	Wisconsin Bone Club, Greenlake, Wisconsin "Update on Alendronate for Corticosteroid-induced Osteoporosis"
1998	Iowa Arthritis Health Professionals, Pre-symposium Course "Update in Osteoporosis"
1998	Pan American League Against Rheumatism (PANLAR) Meeting, Montreal, Canada, "Prevention of Glucocorticoid-induced Osteoporosis"
1998	Duke University, Rheumatology Rounds "Glucocorticoid-induced Osteoporosis".
1998	Canadian Society of Nephrology, Toronto, Canada "Steroid-Induced Osteoporosis"
1998	University of Illinois at Chicago, Grand rounds and Problem Based Active Learning Program in Osteoporosis
1998	Vanderbilt University, Rheumatology Grand Rounds "Glucocorticoid-induced Osteoporosis"
1998	Wake Forest University- Bowman Grey School of Medicine, Rheumatology Update for the Primary Care Physicians,
1998	University of Alabama at Huntsville, Rheumatology for Primary Care Providers
1998	Boston University, Medical Grand Rounds, "Steroid-Induced Osteoporosis"
1998	University of Alabama School of Medicine/Huntsville Program, Neurology/Rheumatology Update
1999	University of Virginia, Medical Grand Rounds, "Steroid-Induced Osteoporosis" Charlottesville, VA
1999	Southeastern Clinical Club, "Steroids and Bone", Birmingham, AL
1999	Hennepin County Medical Center, "Osteoporosis A Clinical Perspective", Minneapolis, MN.
1999	North Carolina Medical Society, "Steroid-induced Osteoporosis" Charlotte, NC.
1999	Alabama Medical Directors' Association, Destin, FL "Osteoporosis Update"
1999	Baptist Center for Medical Education, Music City Rheumatology, Nashville, TN, "Corticosteroid Induced Osteoporosis"
1999	17 th Annual Rheumatology on the Beach Meeting, Destin, FL, "Corticosteroid-Induced Osteoporosis"
1999	44 th Annual Lowe Conference on Rheumatic Diseases, Nauvoo, AL, "Steroids and Bone"
1999	UAB Medwise Mini-Medical School, Birmingham, AL, "Osteoporosis"
1999	Gunderson Clinic, Medical Grand Rounds, LaCross, WI, "Glucocorticoid-Induced Osteoporosis"
1999	Minnesota Rheumatology, Minneapolis, MN, "Glucocorticoid-Induced Osteoporosis"
1999	University of Rochester, Rochester, NY, Arthritis & Osteoporosis Conference, Rochester, NY, "Pathogenesis and Treatment of Steroid Induced Osteoporosis"
1999	ACR National Meeting, RA Study Group, Boston, MA, "Consensus Statements on the Use of Glucocorticoids in Rheumatoid Arthritis"

- 1999 ACR National Meeting, Post-meeting Symposia, Boston, MA, "Variations in Osteoporosis Management- Improving Process of Care and Patient Outcomes"
- 1999 Carraway Medical Center, Birmingham, AL, Medical Grand Rounds
"Glucocorticoid-induced Osteoporosis"
- 2000 Oregon Health Sciences University, Portland, OR, Rheumatology Grand Rounds,
"Glucocorticoids in Rheumatoid Arthritis: The good, the bad, the bone"
- 2000 University of Washington, Seattle, WA, Medicine Noon Conference,
"Glucocorticoid-Induced Osteoporosis"
- 2000 St. Vincent's Hospital, Pittsburgh, PA, Medical Grand Rounds
"Glucocorticoid-induced Osteoporosis"
- 2000 Baptist Medical Center East, Montgomery, AL, Medical Grand Rounds
"Glucocorticoid-Induced Osteoporosis"
- 2000 Southern Medical Association Annual Osteoporosis Course
"Glucocorticoid-induced Osteoporosis – Calcitonin"
- 2000 American College of Rheumatology Spring Clinical Meeting, New Orleans, LA,
"Glucocorticoid-Induced Osteoporosis"
- 2000 University of Nebraska, Omaha, NE, Medical Grand Rounds
"Glucocorticoid-Induced Osteoporosis"
- 2000 Rheumatoid Arthritis Investigator Network (RAIN), Omaha, NE, Visiting
Professor, "Glucocorticoids in Rheumatoid Arthritis"
- 2000 Venezuelan Society of Menopause and Osteoporosis, Caracas, Venezuela.
"Glucocorticoid-Induced Osteoporosis"
- 2000 Louisiana State University, Shreveport, LA, Family Practice Grand Rounds
"Glucocorticoid-induced Osteoporosis"
- 2000 State University of New York (SUNY), Syracuse, NY, Endocrinology Grand
Rounds, "Case Studies in Glucocorticoid-Induced Osteoporosis"
- 2000 Penn State University, Hershey PA, Internal Medicine Grand Rounds, "Steroid-
Induced Osteoporosis"
- 2000 Mayo Clinic, Rochester, MN, Endocrinology Grand Rounds, "Glucocorticoid-
Induced Osteoporosis"
- 2000 American College of Rheumatology National Meeting, "State-of-the-Art Lecture:
Glucocorticoid-Induced Osteoporosis"
- 2001 University of Tennessee at Chattanooga, Internal Medicine Grand Rounds,
"Steroid-Induced Osteoporosis"
- 2001 University of Louisville School of Medicine, Grand Rounds, "Glucocorticoid-
Induced Osteoporosis"
- 2001 Louisiana State University Shreveport, Medical Grand Rounds, "Glucocorticoid-
Induced Osteoporosis"
- 2001 University of North Carolina at Chapel Hill, Rheumatology Grand Rounds,
"Glucocorticoid-Induced Osteoporosis"
- 2001 Cleveland Rheumatology Review, "Glucocorticoid-Induced Osteoporosis"
- 2001 University of Texas Medical Branch, Galveston, TX, Medicine Grand Rounds,
"Glucocorticoid-Induced Osteoporosis"
- 2001 Vanderbilt University, Nashville, TN. Rheumatology Grand Rounds,
"Osteoporosis 2001"
- 2001 Mexican Society of Rheumatology, Mexico City, D.F., Mexico, Annual Visiting
Professor, "Glucocorticoids in Rheumatoid Arthritis: Balancing the Evidence"
- 2001 Pennsylvania Osteoporosis Society Second Symposia on Bone, Philadelphia, PA
"Steroid-Induced Osteoporosis", "Bisphosphonates and Calcitonin"
- 2001 Harvard Advance Rheumatology, Boston, MA "Glucocorticoid-Induced
Osteoporosis", "Osteoporosis 2001"
- 2001 Medical College of Georgia, Augusta, GA, Medical Grand Rounds,
"Glucocorticoid-Induced Osteoporosis"

- 2001 Eastern Carolina University, Greenville, NC, Medical Grand Rounds, "Glucocorticoid-Induced Osteoporosis"
- 2002 Medical University of South Carolina, Charleston, SC, Rheumatology Grand Rounds, "Glucocorticoid-Induced Osteoporosis"
- 2002 American College of Physician Hawaii Chapter Meeting, "Osteoporosis 2002", Honolulu, HI
- 2002 University of Mississippi, Rheumatology Division, "Glucocorticoid-Induced Osteoporosis Case Studies", Jackson, MS
- 2002 Tennessee Society of Allergy, "Glucocorticoid-Induced Osteoporosis", Richmond, TN
- 2002 Medical College of Virginia, Rheumatology and Endocrinology Grand Rounds, "Patient Preferences and Provider Practices in Osteoporosis", "Balancing the Evidence: Glucocorticoids in Rheumatoid Arthritis", Richmond, VA
- 2002 American College of Physicians Alabama Chapter Meeting, "Osteoporosis 2002", Perdido Beach, FL
- 2002 European Workgroup on Glucocorticoids, "Glucocorticoid Drug Interactions", Coimbra, Portugal
- 2002 American College of Rheumatology National Meeting, AF Grant Symposia, "Genetic Determinants of Elderly Onset Rheumatoid Arthritis: Research in Progress", New Orleans, LA
- 2002 American College of Rheumatology National Meeting, Clinical Symposium, "Pro/Con Debate: Consequences of Chronic Glucocorticoid Use in Late Rheumatoid Arthritis", New Orleans, LA
- 2002 Bowman-Grey Bone Club, "Glucocorticoid-Induced Osteoporosis", Winston-Salem, NC
- 2002 University of Maryland Rheumatology Grand Rounds, "Patient Preferences and Provider Practices in Musculoskeletal Disorders", Baltimore, MD
- 2003 International Congress on Glucocorticoid-Induced Osteoporosis, "ACR and Other Recent Guidelines on GIOP Prevention and Treatment", Turin, Italy
- 2003 Emory University Advances in Osteoporosis and Bone Densitometry "Glucocorticoid-Induced Osteoporosis", Atlanta, GA
- 2003 University of Tennessee "Osteonecrosis- When Good Bone Goes Bad", Memphis, TN
- 2003 Bristol Meyer Squibb Pharmacovigilance Grand Rounds "Improving Outcomes in Rheumatoid Arthritis", Princeton, NJ
- 2003 Santa Fe Bone Symposia, "Osteoporosis in the Rheumatic Diseases", "Bisphosphonate Combination Therapy", Santa Fe, NM
- 2003 Johns Hopkins University, Rheumatology Grand Rounds, "Glucocorticoid-Induced Osteoporosis- How Can We Improve Quality of Care?", Baltimore, MD
- 2003 Alabama Academy of Family Practice, Winter Symposia, "Osteonecrosis", "Improving Safe Use of Medicines in Arthritis", Birmingham, AL
- 2004 Winter Rheumatology Symposia, "Bone Diseases in Rheumatology", Osteoporosis Treatment Update", Aspen, CO
- 2004 Eisenberg Memorial Lectureship, "How Can We Improve Quality of Care in Musculoskeletal Disorders", Atlanta, GA
- 2004 Cedar Sinai Rheumatology Grand Rounds, "Improving Care in Glucocorticoid-Induced Osteoporosis", Los Angeles, CA
- 2004 Tufts University, Rheumatology Grand Rounds, "Improving Care in Glucocorticoid-Induced Osteoporosis", Boston, MA
- 2004 Iowa Rheumatology Symposia, "Osteoporosis Update 2004", "Bone Diseases in Rheumatology", Iowa City, IA
- 2004 Southeast Dermatology Society Annual Meeting, "Osteoporosis for Dermatologists", Birmingham, AL

- 2004 American College of Rheumatology Annual Meeting, Clinical Symposia on Gout, "The Evolving Epidemiology of Gout", San Antonio, TX
- 2004 University of Pennsylvania Medicine Grand Rounds, "Osteoporosis in 2004: What's Hot and What's Not", Philadelphia, PA
- 2005 Emory University, Rheumatology Grand Rounds, "Glucocorticoids in RA, Old Friend and Old Foe", Atlanta, GA
- 2005 American College of Rheumatology Innovative Therapies, "Methods to Improve Therapeutic Safety," Washington, D.C.
- 2005 Medicare Advisory Committee Invited Speaker "Vertebroplasty", Baltimore, MD
- 2005 AHRQ Drug Safety Symposia, "Improving Care in Glucocorticoid-Induced Osteoporosis", "Assessing Therapeutic Safety in Gout", Washington, D.C.
- 2005 Penn State University, Endocrine Grand Rounds, "Glucocorticoid-Induced Osteoporosis", Hershey, PA
- 2005 Arthritis Foundation Annual Research Conference, Plenary Session moderator and lecturer: "Pharmacoepidemiology", Atlanta, GA
- 2005 American Society for Bone and Mineral Research 27th Annual Meeting: "Steroid-Induced Osteoporosis", Nashville, TN
- 2005 4th International Congress on Glucocorticoid Induced Osteoporosis: "Updates on Bisphosphonates", Trieste, Italy
- 2005 George Washington University, Rheumatology Grand Rounds, "Glucocorticoid-Induced Osteoporosis, Washington, DC
- 2005 American College of Rheumatology, Satellite Symposia, "Do Gains in BMD Matter, Are Changes in Biochemical Measures of Bone Remodeling Clinically Useful?", San Diego, CA
- 2006 International Society of Clinical Densitometry, " Glucocorticoid and Other Non-menopausal Causes of Osteoporosis", San Diego, CA
- 2006 Indiana University, Division of Rheumatology, "Gout Update 2006", Indianapolis, IA
- 2006 American Geriatrics Society, Annual Meeting, "Methods to Improve Care in Osteoporosis", Chicago, IL
- 2006 McMasters University, Rheumatology Grant Rounds, "Opportunities and Challenges in Improving Osteoporosis Care", Hamilton Ontario, Canada
- 2006 University of Arkansas, Endocrinology Grand Rounds, "Opportunities and Challenges in Improving Osteoporosis Care", Little Rock, AK
- 2006 Mayo Clinic, Endocrinology Grand Rounds, "Opportunities and Challenges in Improving Osteoporosis Care", Rochester, MN
- 2006 Cleveland Bone Club, "Osteoporosis Update", Cleveland, OH
- 2006 American College of Rheumatology/American Board of Internal Medicine, Rheumatology Board Review, "Osteoporosis and Gout", Washington, DC
- 2006 American College of Rheumatology, Clinical Symposia, "Quality of Care in Gout and Nonpharmacologic Approaches to Therapy", Washington, DC
- 2006 American College of Rheumatology, Post-meeting Symposia, "The Epidemiology of Gout", Washington, DC
- 2007 UAB Department of Obstetrics and Gynecology, Progress Symposia, "Osteoporosis Screening and Treatment", Birmingham, AL
- 2007 University of Wisconsin, Endocrinology Grand Rounds, "Update on Glucocorticoid-induced Osteoporosis", Madison WI
- 2007 National Osteoporosis Symposia, 7th International Symposia, "Performance Measures for Osteoporosis", Washington, DC

- 2007 University of California, Los Angeles, 25th Carl M. Pearson Memorial Symposia, "Osteoporosis and Osteopenia," "Gout 2007", Rancho Mirage, CA
- 2007 American Geriatric Society, Annual Meeting, "Barriers to Optimal Osteoporosis Care: How Can We Improve", Seattle, WA
- 2007 The Foundation for Better Health Care, "Treating Osteoporosis in the New Era: Examining the Function and Structure of Bone", Chicago, IL
- 2007 University of Rochester, Orthopedics Grand Rounds, "Opportunities and Challenges to Improve Osteoporosis Care", Rochester, NY
- 2007 UAB Center of Metabolic Bone Disease, "Opportunities and Challenges to Improve Care in Glucocorticoid-Induced Osteoporosis", Birmingham, AL
- 2007 Strong Memorial Hospital, University of Rochester, Orthopedics Grand Rounds: "Opportunity and Challenges to Improve Osteoporosis Care", Rochester, NY
- 2007 University of Pittsburgh School of Medicine "Opportunity and Challenges to Improve Osteoporosis Care", Pittsburgh, PA
- 2007 International Society of Clinical Densitometry, "Update on Epidemiology and Treatment", Lima, Peru
- 2007 Peruvian Society of Rheumatology, "Improving Care in Osteoporosis Opportunities and Challenges", Lima, Peru
- 2007 American Society for Bone and Mineral Research 29th Annual Meeting, "Management of Glucocorticoid-Induced Osteoporosis", Honolulu, HI
- 2007 ACR Time of Quality Measures Clinical Symposium, "Rheumatoid Treatment Guidelines", Boston, MA

GRANT SUPPORT (PAST AND CURRENT):

Financial Resources (Grants and Contracts)

A. Federal:

<u>Title</u>	<u>Period</u>	<u>Amount</u>
NIH-GCRC-CAP: Pharmacoeconomic Evaluations of Low-Dose Corticosteroid Therapy in Rheumatoid Arthritis	04/1/96-03/30/98	\$230,400
NIAMS R03: Risk Factors for Osteonecrosis Among Renal Transplant Recipients	09/17/99-08/31/02	\$148,646
AHRQ U18: Centers for Education and Research on Therapeutics (CERTs) of Musculoskeletal Disorders	07/01/00-09/30/03	\$805,000
AHRQ 2 U18: Centers for Education and Research on Therapeutics (CERTs) of Musculoskeletal Disorders	09/30/03-09/29/07	\$3,201,000
AHRQ 3 U18: Deep South Musculoskeletal Centers for Education and Research on Therapeutics (DSM)	09/01/07-08/31/11	\$3,914,184
NIAMS P60: UAB Multipurpose Arthritis and Musculoskeletal Disease Center: Long-term Safety and Toxicity Monitoring Practices for Common Anti-rheumatic Drugs (Saag Project PI)	02/01/00-01/31/02	\$100,000

NIAMS P60: Multipurpose Arthritis and Musculoskeletal Disease Center: Administrative Core, Saag Assistant Director (Kimberly PI)	02/01/00-01/31/02	\$179,595
NIAMS P60: Multidisciplinary Clinical Research Center: Administrative Unit: Saag, Associate Director (Kimberly PI)	01/01/02-06/30/07	\$123,364
NIAMS P60: Multidisciplinary Clinical Research Center: Improving Quality of Care in Steroid-Induced Osteoporosis (Saag Project PI)	01/01/02-06/30/07	\$186,560
Center for Health Care Policy and Evaluation/FDA (Center for Biologics Evaluation and Research) Comprehensive Linked Data Collection of Biological Agents in Rheumatoid Arthritis	09/1/02-09/15/04	\$775,290
NIA R01: Multi-Center Osteoarthritis Study (MOST) (Lewis PI)	09/30/01-07/31/08	\$423,934
NINR R01: Metabolic Bone Disease Among HIV patients (Smith PI)	09/30/02-12/31/03	\$49,911
FDA Center for Devices:	07/01/04-12/31/05	\$59,250
K24 Mid-Career Development Award	06/01/05-05/31/10	\$653,546

B. State:

<u>Title</u>	<u>Period</u>	<u>Amount</u>
Subcontract to Alabama Department of Public Health: CDC National Arthritis Action Plan	10/01/99-07/31/03	\$224,000
Subcontract to Alabama Department of Public Health: CDC National Arthritis Action Plan	07/01/03-06/30/08	\$53,944

C. College of Medicine

<u>Title</u>	<u>Period</u>	<u>Amount</u>
UAB Center for Metabolic Bone Disease: A prospective Investigation of Avascular Necrosis Among Renal Transplant Patients	03/01/99-02/28/00	\$ —

D. Foundation:

<u>Title</u>	<u>Period</u>	<u>Amount</u>
Arthritis Foundation: Clinical Science Grant: Epidemiologic Determinants of Elderly Onset Rheumatoid Arthritis	07/01/97-06/30/00	\$ _____
Arthritis Foundation: Clinical Science Grant: Genetic Determinants of Elderly Onset Rheumatoid Arthritis	07/01/00-06/30/04	\$ _____
Arthritis Foundation, Maryland Chapter: Engalitcheff Arthritis Outcomes Initiative Risk Assessment and Risk Communication for Biological Agents in Rheumatoid Arthritis	12/01/02-11/30/07	\$ _____
Harvard Pilgrim Health Care: A Population Based HMO Study of Gout Pharmacoepidemiology	12/01/04-05/31/06	\$ _____

E. Industry:

<u>Title</u>	<u>Period</u>	<u>Amount</u>
_____ Hormone in Postmenopausal Women with Fractures	7/15/00-12/01/03	\$ _____
_____ for Glucocorticoid- Induced Osteoporosis	07/01/01-12/01/03	\$ _____
_____ Efficacy of _____ In Preventing Subsequent Osteoporotic Fractures	08/20/02-03/31/05	\$ _____
_____ Effects of prior therapy with _____ _____ on clinical effectiveness of _____	03/25/04-09/26/07	\$ _____
_____ Observational Study of _____ Outcomes _____	03/01/04-12/31/09	\$ _____
_____ versus _____ for Glucocorticoid-induced osteoporosis	07/14/04-07/31/07	\$ _____
_____ after either _____ or _____ in Postmenopausal Osteoporosis	03/25/04-09/24/05	\$ _____
_____ Effects of _____ on BMD in Postmenopausal Osteoporosis	11/13/02-10/01/05	\$ _____
_____ Compared to _____ in Post-Menopausal Women with Moderately Severe Osteopenia or Osteoporosis	04/01/04-04/01/08	\$ _____

_____ Osteoporosis Treatment in the Home Health Care Setting	06/15/04-12/31/06	\$ _____
_____ Comparison of _____ and _____ on Lumbar BMD in GIOP	10/20/02-12/31/08	\$ _____
_____ versus _____ in Postmenopausal women with Low BMD	03/31/06-03/31/09	\$ _____
_____ in subject with Low BMD	05/01/07-04/30/09	\$ _____
Women with Postmenopausal Osteoporosis Treated with _____ and _____	10/03/06-05/02/08	\$ _____
_____ Prostate Cancer and Bone Health: Impact of Short-Term Androgen-Deprivation Therapy on Bone Mineral Density	03/21/05-12/31/07	\$ _____
_____ Effects of Combination Therapy of _____ and _____ on Postmenopausal Women with Severe Osteoporosis	10/10/06-06/30/08	\$ _____
_____ Compared w/ _____ on Back Pain in Postmenopausal Women w/Osteoporotic Vertebral Fractures	07/18/06-07/17/09	\$ _____
_____	01/01/07-12/31/08	\$ _____
_____ Osteoporosis in Women _____	10/01/06-12/31/08	\$ _____

F. Other

<u>Title</u>	<u>Period</u>	<u>Amount</u>
American College of Rheumatology: Recommendations for the Use of Biological Agents in the Treatment of Rheumatoid Arthritis	04/01/06-11/31/07	\$ _____
The Public Health Trust: The Marketing of Medicines: Development, Dissemination and Evaluation of a Critical skills Curriculum for Prescribers	11/01/05-10/31/07	\$ _____
United Mine Workers of America: An Evaluation of the Prescription Drug Care Coordination Program of the United Mine Workers of America Health and Retirement Funds	10/01/05-12/31/07	\$ _____

BIBLIOGRAPHY:

Peer Reviewed Manuscripts Published or In Press:

1. Spriegel J, **Saag K**, and Tsang T: Infectious Diarrhea Secondary to Enteromonas Hominis. Am J Gastroenterol, 84(10):1313-1314, 1989.
2. **Saag K**, Goldschmidt R, and Golbus J: An Eosinophilia-Myalgia Syndrome Associated With an L-Tryptophan Containing Product. J. Rheumatol, 17:1551-1553, 1990.
3. **Saag K**, Nieman T, Warner C, and Naides S: Subcutaneous Fat Necrosis Associated with Acute Pancreatitis. J. Rheumatol, 19(4):630-632, 1992.
4. Foto F, **Saag KG**, Scharosch LL, Howard EJ, and Naides SJ: Parvovirus B19-Specific DNA in Bone Marrow from Chronic B19 Arthropathy Patients. Evidence for Viral Persistence. J Inf Dis, 167:744-748, 1993.
5. **Saag K**, Koehnke R, Caldwell J, Brasington R, Burmeister L, Zimmerman B, Kohler J, and Furst D: Low Dose Long-term Corticosteroid Therapy in Rheumatoid Arthritis: An Analysis of Serious Adverse Events. Am J Med, 96:115-123, 1994. (Comments in American Journal of Medicine, 99:692-94, 1995.)
6. **Saag K**, Rubenstein L, Chrischilles E and Wallace R: Nonsteroidal Anti-inflammatory Drugs and Cognitive Decline in the Elderly. J Rheumatol, 22:2142-2147, 1995.
7. Burma M, Rachow J, and **Saag K**: Methotrexate Patient Education: A Quality Improvement Study. Arth Care Res, 9:216-222, 1996.
8. **Saag KG**, Saltzman CL, Brown CK, and Budiman-Mak E: The Foot Function Index for Measuring Rheumatoid Arthritis Pain: Evaluating Side-to-Side Reliability. Foot and Ankle International, 17:506-510, 1996.
9. **Saag KG**, Kolluri S, Koehnke RK, Georgou TA, Rachow JR, Hunninghake GW, and Schwartz DA: Rheumatoid Arthritis Lung Disease: Determinants of Physiologic and Radiologic Abnormalities. Arthritis Rheum, 39:1711-1719, 1996.
10. **Saag KG**, Criswell LA, Sems KM, Nettleman MD, and Kolluri S: and Low-Dose Corticosteroid Therapy in Rheumatoid Arthritis: A Meta-Analysis Review of Moderate-term Effectiveness. Arthritis Rheum, 39:1818-1825, 1996.
11. Mayr NA, Riggs CE, **Saag KG**, Wen BC, Pennington EC, and Hussey DH: Mixed Connective Tissue Disease and Radiation Toxicity: A Case Report. Cancer, 79:612-618, 1997.
12. The Iowa Persian Gulf Study Group, (**Saag KG**, Member of Group): Self-reported Illness and Health Status Among Gulf War Veterans: A Population-Based Study. JAMA, 277(3):238, 1997.
13. **Saag KG**: Health Services Research. Current Opin Rheumatol, 9:118-125, 1997.
14. **Saag KG**, Cerhan JR, Kolluri S, Rachow JR, Hunninghake GW, and Schwartz DA: The Effects of Cigarette Smoking on Rheumatoid Arthritis Disease Severity. Ann Rheum Dis, 56:463-9, 1997.

15. **Saag KG**: The effect of Postoperative Nonsteroidal Anti-inflammatory Drug Administration on Spinal Fusion - Point of View (ed). *Spine*, 23:838, 1998.
16. **Saag KG**, Doebbeling BN, Rohrer JE, Kolluri S, Mitchell TA, and Wallace RB: Arthritis health service utilization among the elderly: the role of urban-rural residence and other utilization factors. *Arthritis Rheum (Arth Care Res)*, 11:177-185, 1998.
17. **Saag KG**, Doebbeling BN, Rohrer JE, Kolluri S, Mitchell TA, and Wallace RB: Arthritis Health Service Utilization Among the Elderly: The Role of Urban-Rural Residence and Other Utilization Factors. *Med Care*, 36:965-976, 1998.
18. **Saag KG**, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG: Alendronate for the treatment and prevention of glucocorticoid induced osteoporosis. *NEJM*, 339:292-9, 1998.
19. Petersen RL, **Saag KG**, Wallace RB, Doebbeling BN: Influenza and pneumococcal vaccine receipt in older persons with chronic disease: A population-based study. *Med Care*, 37:502-509, 1999.
20. Osiri M, **Saag K**, Ford AM, Moreland LW: Practice pattern variation by various specialists in the prevention of glucocorticoid-induced osteoporosis (GIOP). *J Clin Rheumatol*, 6:117-122, 2000.
21. **Saag K**, van der Heijde D, Fisher C, Samara A, DeTora L, Bolognese J, Sperling R, and Daniels B for the Osteoarthritis Studies Group: Rofecoxib, a new specific cyclooxygenase 2 inhibitor shows sustained efficacy comparable to NSAIDs, a six-week and a one-year trial in patients with osteoarthritis. *Arch Fam Med*, 9:1124-34, 2000.
22. Adachi R, **Saag K**, Emkey R, Cividino A, Brown J, Goemaere S, Dumortier T, Daifotis AG, Czachur M, for the Alendronate Study: Effects of Alendronate for Two Years on BMD and Fractures in Patients Receiving Glucocorticoids. *Arthritis Rheum*, 44:202-211, 2001.
23. Merlino L, Bagchi I, Taylor T, Utrie P, Chrischilles E, Sumner III W, Mudano A, **Saag K**: Preferences for fractures and other glucocorticoid-associated adverse effects among rheumatoid arthritis patients. *Med Decis Making*, 2001; 21:122-132.
24. Mudano A, Allison J, Hill J, Rothermel T, **Saag K**: Variations in Glucocorticoid induced Osteoporosis Prevention in a Managed Care Cohort. *J Rheum*, 2001; 28:1298-1305.
25. Kaboli P, Doebbeling B, **Saag KG**, Rosenthal GE. Use of complementary and alternative medicine by older arthritis patients: a population-based study. *Arthritis Rheum (Arth Care Res)*, 2001; 45:398-403.
26. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (**Saag, KS**, Committee member): Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 Update. *Arthritis Rheum*, 2001; 44:1496-1503.
27. Mikuls TR, Kahn D, Utrie PC, Miller SJ, Koehnke R, **Saag KG**: Samarium-153-EDTMP (Sm-153) in the treatment of refractory rheumatoid arthritis. *Scand J Rheum*, 2001; 30:356-9.
28. Gornisiewicz M, Rodriguez M, Smith JK, **Saag K**, Alarcon GS: Grand Rounds from International Lupus Centres protein-losing enteropathy in a young African-American woman with abdominal pain, diarrhea and hydronephrosis. *Lupus*, 2001; 10:835-840.

29. Mikuls T, Cerhan J, Merlino L, Criswell L, **Saag K**: Coffee, tea, and caffeine consumption and risk of rheumatoid arthritis. *Arthritis Rheum*, 2002; 46:83-91.
30. Cerhan JR, **Saag KG**, Criswell L, Merlino LA, Mikuls TR: Blood transfusion, alcohol use and anthropometric risk factors for rheumatoid arthritis in older women. *J Rheumatol*, 2002; 29:246-54.
31. Criswell L, Merlino M, Cerhan J, Criswell L, Mudano A, Mikuls, T, Folsom A, **Saag K**. Cigarette smoking and risk of elderly-onset rheumatoid arthritis: results from the Iowa Woman's Health Study. *Am J Med*, 2002; 112:465-471.
32. Voelker P, **Saag KG**, Schwartz DA, Chrischilles E, Clarke WR, Woolson RF, Doebbeling BN: Health-related Quality of Life in Gulf War Military Personnel. *Am J Epidemiol*, 2002; 155:899-907.
33. Mikuls TR, Saag KG, Criswell LA, et al. : Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the Iowa Women's Health Study *Ann Rheum Dis*. 2002; 61(11):994-9.
34. Furst DE, **Saag K**, Fleischmann R, Sherrer Y, Block J, Rutstein J, Baldassare A, Kaine J, Cash J, Calabrese L, Dietz F, Sack M, Senter RG, Wiesenhutter C, Schiff M, Stein M, Satoi Y, Matsumoto A, Caldwell J, Harris E, Moreland LW, Hurd E, Yocum D, Stamler DA: Efficacy of tacrolimus in rheumatoid arthritis patients who have been unsuccessfully treated with methotrexate: a six-month, double blind, randomized, dose ranging study. *Arthritis Rheum*, 2002; 46:2020-28.
35. Mikuls TR, Julian BA, Bartolucci, A, **Saag KG**: Bone Mineral Density Changes Within Six Months of Renal Transplant. *Transplantation*, 2003; 75:49-54.
36. Cerhan JR, **Saag KG**, Merlino LA, Mikuls TR, Criswell LA: Antioxidant micronutrients and risk of rheumatoid arthritis in a cohort of older women. *Am J Epidemiol*, 2003; 157: 345-354.
37. Mudano A, Casebeer L, Patino F, Allison, JJ, Weissman, NW, Kiefe, CI, Person S, Gilbert D, **Saag K**: Racial disparities in osteoporosis prevention. *South Med J*, 2003;96(5):445-451.
38. Patino FG, Allison JJ, Olivieri JJ, Mudano A, Juarez L, Person S, Mikuls TR, Kovac SH, **Saag KG**: The effects of physician specialty and patient co-morbidities on the use and discontinuation of coxibs. *Arthritis Rheum (Arth Care Res)*, 2003;49(3):293-299.
39. Goemaere S, Liberman UA, Adachi JD, Hawkins F, Lane N, **Saag KG**, Schnitzer T, Kaufman JM, Malice MP, Carofano W, Daifotis A: Incidence of Non-vertebral Fractures in Relation to Time on Treatment and Bone Density in Glucocorticoid Treated Patients: A Retrospective Approach . *J Clin Rheumatol*, 2003;9:170-175.
40. Kirwan J, Heiberg T, Hewlett S, Hughes R, Kvien T, Ahlmén M, Boers M, Minnock P, **Saag K**, Shea B, Almazor MS, Taal E: Outcomes from the Patient Perspective Workshop at OMERACT 6. *J Rheumatol*, 2003; 30:868-872.
41. Merlino LA, Cerhan JR, Criswell L, Mikuls T, **Saag KG**: Estrogen and other female reproductive factors are not strongly associated with the development of rheumatoid arthritis in elderly women. *Semin Arthritis Rheum*, 2003; 33:72-82.

42. Mikuls TR, Mudano AS, Pulley L, **Saag KG**: The association of race/ethnicity with the receipt of traditional and alternative arthritis-specific healthcare. *Med Care*, 2003; 41:1233-1239.
43. Mikuls T, **Saag K**, Criswell L, Merlino L, Cerhan JR: Health related quality of life in women with elderly onset rheumatoid arthritis. *J Rheumatol*, 2003; 30:952-957.
44. Patino FG, Olivieri JJ, Allison J, Mikuls TR, Moreland LW, Kovac SH, Juarez L, Person S, **Saag KG**: Nonsteroidal anti-inflammatory drug toxicity monitoring and safety practices. *J Rheumatol*, 2003;30:2680-2688.
45. Bijlsma JWJ, Boers M, **Saag K**, Furst DE: Glucocorticoids in the treatment of early and late rheumatoid arthritis. *Ann Rheum Dis*, 2003; 62:1033-1037.
46. Merlino LA, Cerhan JR, Criswell LA, Mikuls TR, Curtis, J, and **Saag KG**: Association of Vitamin D Intake with Incidence of Rheumatoid Arthritis (RA) in Older Women: Results from the Iowa Women's Health Study. *Arthritis Rheum*, 2004; 50(1):72-77.
47. Mikuls TR, Allison J, Patino F, Olivieri J, MacLean CH, **Saag KG**: Quality indicators for gout management. *Arthritis Rheum*, 2004; 50(3):937-943.
48. MacLean CH, **Saag K**, Solomon DH, Morton SC, Klippel JH: Measuring Quality in Arthritis Care: Methods for Developing the Arthritis Foundation's Quality Indicator Set. *Arthritis Rheum (Arth Care Res)*, 2004; 51(2):193-202.
49. Lopez BR, Mikuls TR, Moore DS, Julian BA, Bernreuter WK, Elkins M, **Saag KG**: Incidence of hip osteonecrosis among renal transplant recipients: a prospective study. *J Clin Radiol*, 2004; 59:431-438.
50. **Saag KG**, Olivieri JJ, Patino F, Mikuls TR, Allison JJ, MacLean C: Measuring quality in arthritis care: the Arthritis Foundation's quality indicator set for analgesics. *Arthritis Rheum (Arth Care Res)*, 2004; 51:337-49.
51. Colón-Emeric CS, Casebeer L, **Saag K**, Allison J, Levine, Suh T, Lyles, KW: Barriers to providing osteoporosis care in skilled nursing facilities: perceptions of medical directors and directors of nursing. *J Am Med Directors*, 2004; 5(6):361-66.
52. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, **Saag KG**: Gout epidemiology: results from the UK General Practice Research Database, 1990–1999. *Ann Rheum Dis*, 2005; 64:267-272.
53. Pisu M, James N, **Saag KG**: The cost of glucocorticoid-associated adverse events in rheumatoid arthritis. *Rheumatology*, 2005; 44:781-788.
54. Mikuls TR, **Saag KG**, George V, Mudano AS, Banerjee S: Racial Disparities in the Receipt of Osteoporosis Related Healthcare among Community-Dwelling Older Women with Arthritis and Previous Fracture. *J Rheumatol*, 2005; 32:870-875.
55. Mikuls TR, **Saag KG**, Curtis J, Bridges SL Jr, Alarcon GS, Westfall AO, Lim SS, Smith EA, Jonas BL, Moreland LW, and the CLEAR Investigators: Prevalence of osteoporosis and osteopenia among African Americans with early rheumatoid arthritis: the impact of ethnic-specific normative data. *J Natl Med Assoc*, 2005; 97(8):1155-1160.

56. Curtis J, Westfall AO, Allison JJ, Becker A, Casebeer L, Freeman A, Spettell CM, Weissman NW, Wilke S, **Saag K**: Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. *Arthritis Rheum*, 2005; 52(8):2485-2494.
57. Mikuls TR, Farrar JT, Bilker WB, Fernandex S, **Saag KG**: Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricemia: results from the UK General Practice Research Database (GPRD). *Rheumatology*, 2005; 44(8):1038-1042.
58. Curtis J, Olivieri J, Allison J, Person S, Juarez L, Kovac S, Gaffo A, **Saag KG**: A group randomized trial to improve safe use of nonsteroidal anti-inflammatory drugs. *Am J Managed Care*, 2005; 11:537-43.
59. King A, **Saag KG**, Burge RT, Pisu M, Goel N: Fracture Reduction Affects Medicare Economics (FRAME): impact of increased osteoporosis diagnosis and treatment, *Osteoporos Int*, 2005; 16(12):1545-57.
60. Shatin D, Rawson NS, Curtis JR, Braun MM, Martin, CK, Moreland LW, Becker, AF, Patkar, NM, Allison, JJ, **Saag KG**: Documented Tuberculin Skin Testing Among Infliximab Users Following a Multi-modal Risk Communication Interventions. *Pharmacoepidemiol Drug Saf*, 2006; 15(1):11-8.
61. Curtis J, Smith B, Weaver M, Landers K, Lopez-Ben R, Raper J, Saag M, Venkataraman R, **Saag KG**: The effect of ethnicity on metabolic bone disease among HIV positive patients with lipodystrophy. *AIDS Res Hum Retroviruses*, 2006; 22(2):125-31.
62. Kovac SH, Patino F, Mikuls T, Mudano A, **Saag KG**: Health-Related Quality of Life Among Self-Reported Arthritis Sufferers: Effects of Race/Ethnicity and Residence. *Qual Life Res*, 2006; 15(3):451-60.
63. Mikuls TR, Curtis J, Allison JJ, Hicks RW, **Saag KG**: Medication Errors with the Use of Allopurinol and Colchicine: Results from a National Anonymous, Internet-Accessible Error Reporting System. *J Rheumatol*, 2006; 33(3):562-6.
64. Abdolrasulnia M, Weichold N, Shewchuk R, **Saag K**, Daniel J, Cobaugh DJ, LaCivita C, Weissman N, Allison J: Non-steroidal Anti-Inflammatory Medication: Do Medical Records Agree with Patient Self Report? *Am J Health Syst Pharm*, 2006; 63(8):744-7.
65. **Saag KG**, Gehlbach SH, Curtis JR, Youket TE, Worley K, Lange JL: Trends in prevention of glucocorticoid-induced osteoporosis. *J Rheumatol*, 2006; 33(8):1651-7.
66. Curtis JR, Westfall AO, Allison J, Bijlsma JWJ, Freeman A, George V, Kovac S, Spettell C, **Saag KG**: Population-based assessment of adverse events associated with chronic glucocorticoid use. *Arthritis Rheum*, 2006; 55(3):420-426.
67. Curtis JR, Westfall AO, Allison J, Freeman A, Kovac SH, **Saag KG**: Agreement and Validity of Pharmacy Data Versus Self-Report for Use of Osteoporosis Medications among Chronic Glucocorticoid Users. *Pharmacoepidemiol Drug Saf*, 2006; 15(10):710-8.

68. Hughes LB, Beasley TM, Patel H, Tiwari HK, Morgan SL, Baggott JE, **Saag KG**, McNicholl J, Moreland L, Alarcón GS, Bridges SL: Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis. *Ann Rheum Dis*, 2006; 65(9):1213-8.
69. Curtis JR, Westfall AO, Allison JJ, Freeman A, **Saag KG**: Channeling and adherence with Alendronate and Risedronate among Chronic Glucocorticoid Users. *Osteoporos Int*, 2006; 17(8):1268-74.
70. Harrold LR, Yood RA, Mikuls TR, Andrade SA, Davis J, Fuller J, Chan KA, Roblin D, Raebel MA, Von Worley A, Platt R, **Saag KG**: Sex differences in gout epidemiology, evaluation and treatment. *Ann Rheum Dis*, 2006; 65(10):1368-72.
71. Criswell LA, **Saag KG**, Mikuls TR, Cerhan JR, Merlino LA, Lum RF, Pfeiffer KA, Woehl B, Seldin MF: Smoking interacts with genetic risk factors in the development of rheumatoid arthritis. *Ann Rheum Dis*, 2006; 65(9):1163-7.
72. Sarawate C, Yang W, Patel P, Schumacher HR, **Saag K**, Bakst A: Gout medication treatment patterns, and adherence to standards of care, from a managed care perspective. *Mayo Clin Proc*, 2006; 81(7):925-34.
73. Levine DA, **Saag KG**, Casebeer LL, Colon-Emeric C, Lyles KW, Shewchuk RM: Using a modified nominal group technique to elicit director of nursing input for an osteoporosis intervention. *J Am Med Dir Assoc*, 2006; 7(7):420-5.
74. Curtis JR, Kim Y, Bryant T, Scott D, Meadows E, **Saag KG**: Osteoporosis in the Home Health Care Setting: A Window of Opportunity? *Arthritis Rheum (Arthritis Care & Res)*, 2006 15:55(6); 971-5.
75. Bonnick S, **Saag KG**, Kiel D, McClung M, Hochberg M, Burnett S-A, Sebba A, Kagan R, Chen E, Thompson DE, de Papp AE: Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risendronate over two years, *J Clin Endocrinal Metab*, 2006; 91(7):2631-7.
76. Harrold LR, Yood RA, Mikuls TR, Andrade SA, Fouayz H, Davis J, Chan KA, Raebel MA, Von Worley A, Platt R, **Saag KG**: Validity of Gout Diagnoses in Administrative Data, *Arthritis Rheum*, 2007; 57(1):103-108.
77. Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, Shatin D, **Saag KG**: Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. *Arthritis Rheum*, 2007; 56(4):1125-1133.
78. Curtis JR, Westfall AO, Allison J, Becker A, Melton ME, Freeman A, Kiefe CI, MacArthur M, Ockershausen T, Stewart E, Weissman N, **Saag KG**: Challenges in improving the quality of osteoporosis care for long-term glucocorticoid users: a prospective, randomized trial. *Arch Intern Med*, 2007; 167(6):591-6.
79. Colon-Emeric C, Lyles KW, Levine DA, House P, Schenck A, Gorospe J, Fermazin M, Oliver K, Alison J, Weisman N, Xie A, Curtis JR, Saag K: Prevalence and predictors of osteoporosis treatment in nursing home residents with known osteoporosis and recent fracture. *Osteoporos Int*, 2007; (4):553-9.
80. Curtis JR, Martin C, **Saag KG**, Patkar N, Shatin D, Kramer J, Allison JJ, Braun MM: Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs. *Arthritis Rheum (Arth Care Res)*, 2007 57(2):343-6.

81. **Saag K**, Lindsay R, Kriegman A, Beamer E, Zhou W: A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. *Bone*, 2007 40(5):1238-43.
82. Kirwan JR, Minnock P, Adebajo A, Bresnihan B, Choy E, de Wit M, Hazes M, Richards P, **Saag K**, Suarez-Almazor M, Wells G, Hewlett S: Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. *J Rheumatol*, 2007; 34(5):1174-7.
83. Colon-Emeric CS, Lyles KW, House P, Levine DA, Schenck AP, Allison J, Gorospe J, Fermazin M, Oliver K, Curtis JR, Weissman N, Xie A, **Saag KG**: Randomized Trial to Improve Fracture Prevention in Nursing Home Residents. *Am J Med* 2007; 120:886-892.
84. Curtis JR, Kramer JM, Martin C, **Saag KG**, Patkar N, Shatin D, Burgess M, Xie A, Braun MM, Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF- α antagonists *Rheum (Oxford)* 2007 Nov;46(11):1688-93.
85. **Saag KG**, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R: Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis., *N Engl J Med*, 2007 Nov 15;357(20):2028-2039
86. Fry R, Ray MN, Cobaugh D, Weismann N, Kiefe C, **Saag K**, Curtis J, Allison J, Shewchuk R: Racial/Ethnic Disparities in Patient-Reported NSAID Risk Awareness, Patient-doctor NSAID Risk Communication, and NSAID Risk Behavior, in press, *Arthritis Care & Research*.

Books and/or Book Chapters:

1. **Saag K**, Kline J, and Hunninghake G: Interstitial Lung Diseases. In Textbook of Pulmonary Medicine, 6th Edition, Lippincott-Raven, 1997.
2. Cush J, Kavanaugh A, Olson N, Stein M, Kazi S, **Saag K**: Rheumatology: Diagnosis and Therapeutics. Williams and Wilkins, 1999.
3. Utrie P, Burma M, and **Saag K**: "Rheumatology". In Primary Care Patient Teaching Guides, Ferri FF (ed.), Chicago, Mosby Yearbooks, 1999.
4. Morgan S, **Saag K**, Julian B, Blair H: "Osteopenic Bone Diseases" In Arthritis and Allied Conditions, 14th edition, Koopman WJ (ed), Williams & Wilkins, 2000.
5. Peterson E, **Saag K**: "Reflex Sympathetic Dystrophy" In Treatment of the Rheumatic Diseases, 2nd edition, Weissman MH, Weinblatt ME, Louie J. (eds). W.B. Saunders, 2000.
6. Committee on Identifying Effective Treatments for Gulf War Veterans' Health Problems (**Saag, KG**, Committee member): "Gulf War Veterans – Treating Symptoms and Syndromes". National Academy Press, Washington, D.C., 2001.
7. **Saag KG**, Kirwin J: "Glucocorticoid Therapy in Rheumatoid Arthritis" In Modern Therapeutics of Rheumatoid Diseases. Tsokos GC (ed.), Humana Press, 2001.
8. **Saag KG**, Morgan SL, Julian BA: "Osteopenic Bone Disorders" In Clinical Primer of Rheumatology, Koopman W, Boulware D, Heudebert G (eds), 2003, pp. 278-295.
9. **Saag K**, Morgan S, Cao X: "Osteopenic Bone Diseases" In Arthritis and Allied Conditions, 15th edition, Koopman WJ (ed), Lippincott, Williams & Wilkins, 2004, pp. 2473-2541.

10. Curtis JR, **Saag K**: "Treatment of Glucocorticoid-Induced Osteoporosis". In: Bone Disease in Rheumatology, Maricic M, Gluck OS (eds.). Philadelphia: Lippincott Williams & Wilkins, 2005, pp. 111-119.
11. **Saag K**, Mikuls T, Abbott J: "The Epidemiology of Gout" In Crystal-Induced Arthropathies, Wortmann R, Schumaker R, Becker M (eds.), Informa: New York, 2006, pp.7-37.
12. **Saag K**: "Systemic Glucocorticoids in Rheumatology " In Rheumatology 4e, Hochberg M, Silman A, Smolen J, Weinblatt M, and Weissman (eds.), in press, 2006.
13. **Saag KG**: "Epidemiology and Diagnosis of Osteoporosis," In Primer of the Rheumatic Diseases, 12th Ed in press, 2007.

Electronic Media:

1. **Saag KG** and Furst DE: CD-ROM "Cards" entitled "Major Corticosteroids Side Effects", "Corticosteroid Withdrawal Regimens", "Major Side effects of Inhaled Corticosteroids". In: Up To Date in Medicine, version 8.3, B.D. Rose (ed.), 2000.

Published Abstracts:

1. **Saag K**, Goldschmidt R, and Globes J: Proliferative Glomerulonephritis (PGN) and Diffuse Pulmonary Hemorrhage (DPH): Report of 5 Cases of a Goodpasture-Like Illness Without Anti-GBM Antibodies. *Arthritis Rheum*, 32(9):R31, 1989.
2. **Saag K**, Koehnke R, Caldwell J, Brasington R, Burmeister L, Kohler J, and Furst D: Long-term Low Dose Corticosteroid Therapy in 224 Rheumatoid Arthritis Patients: Analysis of Adverse Events. *Arthritis Rheum*, 35(9):S233, 1992.
3. Burma M, Rachow J, Yagla S, and **Saag K**: Methotrexate Patient Education: A Quality Improvement Study. *Arthritis Care Res*, 6(4):S23, 1993.
4. **Saag KG**, True C, and Naides SJ: Intravenous Immunoglobulin Treatment of Chronic Parvovirus B19 Arthropathy. *Arthritis Rheum*, 36(9):S67, 1993.
5. **Saag K**, Rubenstein L, Chrischilles E and Wallace R: Nonsteroidal Anti-inflammatory Drugs and Cognitive Decline in the Elderly. *Arthritis Rheum*, 37(9):S197, 1994.
6. Sems KM, Criswell LA, Nettleman MD, Kolluri S, and **Saag KG**: Low-dose Corticosteroid Therapy in Rheumatoid Arthritis: A Systematic Review of Effectiveness. *Arthritis Rheum*, 38(9):S312, 1995.
7. **Saag KG**, Kolluri S, Koehnke RK, Georgou TA, Hunninghake GW, and Schwartz DA: Rheumatoid Arthritis Lung Disease: Determinants of Physiologic and Radiologic Abnormalities. *Arthritis Rheum*, 38(9):S364, 1995.
8. Ohashi K, **Saag KG**, Shin MJ, Daniel WW, and El-Khoury GY: A New Global Scoring Method for Rheumatoid Arthritis: Assessment of Reliability and Clinical Predictive Value. *Radiology*, 197(P):265, 1995.

9. **Saag KG**, Doebbeling BN, Kolluri S, Herman ME, Rohrer JE, and Wallace RB: Variation in Tertiary Prevention Among the Elderly Due to Urban-Rural Residence and Other Access Factors. *J of Gen Int Med*, 11(Suppl. 1):84, 1996.
10. **Saag KG**, Doebbeling BN, Kolluri S, Mitchell T, and Wallace RB: Variation in Arthritis Health Service Utilization Among the Elderly Due to Urban-Rural Residence and Other Access Factors. *Arthritis Rheum*, 39:S318, 1996.
11. **Saag KG**, Cerhan JR, Kolluri S, Hunninghake GW, and Schwartz DA: Cigarette Smoking and Rheumatoid Arthritis Severity. *Arthritis Rheum*, 39:S301, 1996.
12. Taylor T, Redford T, **Saag K**, Barnett M: Rheumatoid Arthritis Medical Care Use and Expenditures in an Adult Non Elderly Medicaid Population. *Arthritis Rheum*, 39:S71, 1996.
13. Goemaere S, Adachi J, Hawkins F, Lane N, Poubelle P, **Saag K**, Schnitzer T, Malice M-P, Freedholm D, Czachur M, and Daifotis A: Nonvertebral Fracture and Bone Density in Glucocorticoid-Treated Patients. *Arthritis Rheum*, 39:S88, 1996.
14. Doebbeling BN, Rohrer JE, Woolson RF, Torner JC, **Saag KG**, et al: Health services Utilization Among Persian Gulf War and Activated Non-Deployed Veterans. Abstracts of the 125th Annual Meeting of the American Public Health Association, Indianapolis, IN, p. 123, 1997.
15. **Saag KG**, Emkey R, Schnitzer T, et al. Alendronate for the Management of Glucocorticoid-Induced Osteoporosis: Results of the Multicenter U.S. Study. *Arthritis Rheum* 1997.
16. Merlino L, Bagchi I, Taylor T, Summner W, Nease R, **Saag K**: Preference Values for Corticosteroid-Associated Adverse Health States in 107 Rheumatoid Arthritis Patients. *Med Decision Making*, 18(4):470, 1998.
17. **Saag K**, Merlino L, Bagchi I, Taylor T, Badreddine H, Utrie P, Myers B: Perceptions of Corticosteroid Effectiveness and Adverse Experiences Among Past and Current Steroid Users. *Arthritis Rheum*, 41(9):S315, 1998.
18. Bagchi I, Taylor T, Merlino L, **Saag K**: Willingness to Pay for a Cure for Rheumatoid Arthritis. *Arthritis Rheum*, 41(9):S225, 1998.
19. Merlino L, Bagchi I, Taylor T, Badreddine H, **Saag K**: Predictors of Preferences for Fracture Associated Health States in 107 RA Corticosteroid Users. *Arthritis Rheum*, 41(9):S226, 1998.
20. Merlino L, Bagchi I, Utrie P, Taylor T, Chrischilles E, Hirokawa R, Gabriel S, Summner W, Nease R, **Saag K**: Preference Values for Fractures and Other Corticosteroid-Associated Adverse Health States in 107 RA Patients. *Arthritis Rheum*, 41(9):S225, 1998.
21. Goemaere S, Correa-Rotter R, **Saag K**, Menkes C-J, Delmas P, Daifotis AG, Malice M-P, Espinosa, D, for the Alendronate Study Group: Alendronate Increases Spine BMD Irrespective of Glucocorticoid Dose or Duration. *J Bone Mineral Res*, 23(5):S182, 1998.
22. **Saag K**, Emkey R, Cividino A, Brown J, Goemaere S, Dumortier T, Daifotis AG, Czachur M, for the Alendronate Study: Effects of Alendronate for Two Years on BMD and Fractures in Patients Receiving Glucocorticoids. *J Bone Mineral Res*, 23(5):S182, 1998.

23. Emkey R, **Saag K**, Brown J, Correa-Rotter R, Malice M-P, Carofano W, Daifotis A: Consistency of Effect of Alendronate in Glucocorticoid-Induced and Postmenopausal Osteoporosis. *Arthritis Rheum*, 41(9):S44, 1998.
24. **Saag K**, Fisher C, McKay J, Ehrich E, Zhao P-L, Bolognese J, Seidenberg B, Daniels B: MK-0966, A Specific COX-2 Inhibitor, Has Clinical Efficacy Comparable to Ibuprofen in the Treatment of Knee and Hip Osteoarthritis (OA) in a 6-Week Controlled Clinical Trial. *Arthritis Rheum*, 41(9):S196, 1998.
25. Kaboli PJ, Doebbeling BN, **Saag, KG**, Rosenthal GE: Use of complementary and alternative medicine by older arthritis patients. *J Gen Intern Med*, 14(1)(suppl):104, 1999.
26. Hill J, Rothermel T, Mudano A, Allison J, **Saag K**: Management of patients at risk for glucocorticoid-induced osteoporosis: predictors of treatment and surveillance in a managed care population. *Arthritis Rheum*, 42(9):S72, 1999.
27. Mudano A, Allison J, Hill J, Rothermel T, **Saag K**: Glucocorticoid-induced osteoporosis: process of care and patient outcomes in a managed care population. *Arthritis Rheum*, 42(9):S73, 1999.
28. Osiri M, **Saag K**, Ford AM, Moreland LW: Practice pattern variation by various specialists in the prevention of glucocorticoid-induced osteoporosis (GIOP). *Arthritis Rheum*, 42(9):S357, 1999.
29. Merlino LA, Cerhan JR, Criswell L, **Saag KG**: Female reproductive factors and the risk of elderly onset rheumatoid arthritis. *Arthritis Rheum*, 43 (S9):S134, 2000.
30. **Saag KG**, Cerhan J, Merlino L, Criswell LA, Mikuls T, Burma M, Mudano A, Folsom A: Cigarette smoking and risk of elderly onset rheumatoid arthritis: Results from the Iowa Women's Health Study. *Arthritis Rheum*, 43 (S9):S167, 2000.
31. Mudano A, Casebeer L, Burst N, Carillo A, Gilbert D, Seay K, **Saag KG**: Racial variation in use of hormone replacement therapy (HRT) and osteoporosis prevention in a large managed care population. *Arthritis Rheum*, 43Suppl(9):S282, 2000.
32. Kahn D, Mikuls TR, Utrie PC, Miller SJ, Koehnke R, **Saag KG**: Samarium-153-EDTMP (Sm-153) in the treatment of rheumatoid arthritis. *Arthritis Rheum*, 43 (S9):S291, 2000.
33. Mikuls TR, Julian BA, Elkins M, Mudano AS, Lopez R, **Saag KG**: Renal transplant recipients lose lumbar BMD within 6 months. *J Bone Min Res*, 16(S1):S545, 2001.
34. Cerhan JR, Merlino LA, Mikuls TR, Criswell LA, **Saag KG**: Antioxidant vitamin intake and risk of elderly onset rheumatoid arthritis: The Iowa Women's Health Study. *Arthritis Rheum*, 44(S9):S104, 2001.
35. Patino F, Mudano A, Allison J, Mikuls TR, Li Q, Moreland LW, Person S, **Saag KG**: Predictors of cyclo-oxygenase (COX)-2 nonsteroidal anti-inflammatory drug (NSAID) use among members of a large managed care organization. *Arthritis Rheum*, 44(S9):S321, 2001.
36. Maisiak RS, **Saag K**, Nunez J, Falkenhagen S, Austin L: Follow-up actions of users of a local arthritis foundation hotline. *Arthritis Rheum*, 44(S9):S321, 2001.

37. Mikuls TR, Cerhan JR, Merlino L, Criswell LA, **Saag KG**: Coffee, tea, and caffeine consumption and risk of rheumatoid arthritis: Results from the Iowa Women's Health Study. *Arthritis Rheum*, 44(S9):S375, 2001.
38. Mikuls TR, Cerhan JR, Merlino L, Moreland LW, Kaslow R, Criswell LA, **Saag KG**: Mortality in elderly-onset rheumatoid arthritis (EORA). *Arthritis Rheum*, 44(S9):S379, 2001.
39. James NT, Austin L, Falkenhagen S, Kohler C, **Saag K**: Identification of potential barriers in delivering the arthritis self help course to rural African Americans in Alabama. *Arthritis Rheum*, 44(S9):S390, 2001.
40. Criswell LA, **Saag KG**, Mikuls TR, Lum RF, Woehl BVM, Merlino LA, Peden EA, Cerhan JR, Seldin MF: The HLA-DRB1 Shared Epitope is Associated with Risk and Severity of Elderly Onset Rheumatoid Arthritis. *Arthritis Rheum*, 46(S9):S506, 2002.
41. King AB, **Saag K**, Burge RT, Balda EP, Pisu M, Goel N: The Budget Impact of Concurrent Bone Mineral Density Testing Rates in the Medicare Program. *Arthritis Rheum*, 46(S9):S538, 2002.
42. Mudano AS, Mikuls TR, Pulley L, **Saag KG**: The Association of Race/Ethnicity and Rural/Urban Residence with the Receipt of Arthritis-Specific Healthcare in a Population-based Cohort of Older Adults. *Arthritis Rheum*, 46(S9):S610, 2002.
43. Mikuls TR, Allison JA, Olivieri JJ, Patino F, MacLean CH, **Saag KG**: The Development of Quality Indicators in Gout Therapy. *Arthritis Rheum*, 46(S9):S625, 2002.
44. Merlino LA, Cerhan JR, Criswell LA, Mikuls TR, **Saag KG**: Vitamin D is Associated with a Lower Risk of Rheumatoid Arthritis (RA) in Older Women: Results from the IOWA Women's Health Study. *Arthritis Rheum*, 46(S9):S455, 2002.
45. Mikuls TR, **Saag KG**, Criswell LA, Merlino LA, Cerhan JR: Health-Related Quality of Life in Women with Elderly-Onset Rheumatoid Arthritis. *Arthritis Rheum*, 46(S9):S247, 2002.
46. Patino FG, Olivieri J, Allison J, Juarez L, Kovac SH, Mikuls TR, Moreland LW, Mudano A, Person S, **Saag KG**: Effects of Physician Specialty on NSAID Toxicity Monitoring in a Managed Care Population. *Arthritis Rheum*, 46(S9):S121, 2002.
47. Pisu M, James NT, **Saag KG**: The Cost of Glucocorticoids in Rheumatoid Arthritis. *Arthritis Rheum*, 46(S9):S167, 2002.
48. James NT, Mikuls TR, Weaver M, **Saag K**: Perception of Exercise among older Adults with Arthritis. *Arthritis Rheum*, 46(S9):S389, 2002.
49. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, **Saag K**: Gout Epidemiology and Pharmacoepidemiology: Results from the General Practice Research Database (GPRD). *Pharmacoepidemiol Drug Saf* 12(S1):S116, 2003.
50. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, **Saag K**: The Treatment of Asymptomatic Hyperuricemia: Results from the General Practice Research Database (GPRD). *Pharmacoepidemiol Drug Saf* 12(S1):S116, 2003.

51. Shatin D, Rawson N, Braun MM, Manda B, Curtis J, Moreland LW, **Saag K**: Impact of Risk Communications on Tuberculosis Testing for Infliximab Users. *Pharmacoepidemiol Drug Saf* 12(S1):S129, 2003.
52. Farrar JT, Mikuls TR, **Saag KG**, Bilker W, Fernandes S, Strom BL: Issues in the Determination of Disease Prevalence from Medical Record Databases: Cumulative Incidence in Chronic Diseases Such as Gout. *Pharmacoepidemiol Drug Saf* 12(S1):S172, 2003.
53. Mikuls TR, **Saag KG**: The Association of Race/Ethnicity with the Receipt of Bone Mineral Density Measurement in a Population-Based Sample at High Risk for Osteoporosis and Fracture. *J Bone Miner Res* 18(S2):S356, 2003.
54. Mikuls TR, **Saag KG**: The Association of Race/Ethnicity with Osteoporosis Evaluation, Treatment, and Prevention in a Population-Based Sample of Older Adults. *Arthritis Rheum*, 48(S9):S83, 2003.
55. Kovac SH, Patino F, **Saag KG**, Mikuls TR: The Association of Race and Residence on HRQoL for Self-Reported Arthritis. *Arthritis Rheum*, 48(S9):S249, 2003.
56. Mikuls TR, **Saag KG**, Westfall AO, Howard G, Lim SS, Smith EA, Jonas BL, Bridges Jr SL, Moreland LW: High Prevalence of Osteopenia/Osteoporosis among African Americans with Early Rheumatoid Arthritis. *Arthritis Rheum*, 48(S9):S299, 2003.
57. Mikuls TR, Farrar JT, Bilker WB, Schumacher Sr HR, Fernandes S, **Saag KG**: Gout Epidemiology: Results from General Practice Research Database (BPRD), 1990-1999. *Arthritis Rheum*, 48(S9):S535, 2003.
58. Curtis J, Shatin D, Rawson NSB, Braun MM, Manda B, Moreland L, Allison J, **Saag KG**: Impact of Risk Communication on Tuberculin Skin Testing for Infliximab and Etanercept Users. *Arthritis Rheum*, 48(S9):S610, 2003.
59. Mikuls TR, Farrar JT, Bilker WB, Schumacher Jr HR, Fernandes S, Allison J, **Saag KG**: The Treatment of Asymptomatic Hyperuricemia: Results from the Population-based General Practice Research Database (GPRD). *Arthritis Rheum*, 48(S9):S612, 2003.
60. Rubash H, Dorr L, Jacobs J, Maloney W, **Saag K**, Malbecq W, Leung A: Does Alendronate Inhibit the Progression of Periprosthetic Osteolysis? Abstracts of the 50th Annual Meeting of the Orthopaedic Research Society, San Francisco, CA, 2004. *Transactions Online* 59:1492.
61. Levine D, **Saag KG**, Casebeer L, Lyles K, Colón-Emeric C, Shewchuk R: Developing a web-based "osteoporosis care toolbox": eliciting input from target users. *J Invest Med* 52(1), 2004.
62. Curtis JR, Smith B, Landers K, Lopez R, Raper J, Saag M, Venkataraman R, Weaver M, **Saag K**: Metabolic Bone Disease among an Ethnically Diverse Cohort of HIV+ Patients with Lipodystrophy. *J Bone Miner Res*, 19(1 Suppl):S299, 2004.
63. **Saag KG**, Gehlbach SH, Curtis JR, Worley K, Youket TE, Lange JL: Temporal Trends in Prevention of Glucocorticoid-Induced Osteoporosis. *J Bone Miner Res*, 19(1 Suppl):S455, 2004.

64. Curtis JR, Allison J, Becker A, Casebeer L, George V, Kovac SH, Spettell C, Westfall A, Weissman N, Wilkie S, **Saag KG**: Screening and Treatment of Glucocorticoid Induced Osteoporosis among 6517 Adults. *J Bone Miner Res*, 19(1 Suppl):S30, 2004.
65. **Saag KG**, Gehlbach SH, Curtis JR, Worley K, Youket TE, Lange JL: Temporal Trends in Prevention of Glucocorticoid-Induced Osteoporosis. *Arthritis Rheum*, 50(S9):S266, 2004.
66. Sharma L, Lewis B, Torner J, **Saag K**, Curtis J, Dunlop D, Webb N, Hietpas J, Nevitt M for the MOST Study Group: The Impact of Gender on Varus-Valgus Laxity in Knees with and without Osteoarthritis. *Arthritis Rheum*, 50(S9):S267, 2004.
67. Hochberg M, Rosen C, Bonnick S, **Saag K**, Broy S, McClung M, Chen E, Petruschke RA, de Papp AE: Once-Weekly Alendronate Has Superior Antiresorptive Efficacy and Comparable Upper Gastrointestinal Tolerability to Once-Weekly Risedronate. *Arthritis Rheum*, 50(S9):S292, 2004.
68. Curtis JR, Allison J, Becker A, Bijlsma JWJ, Casebeer L, George V, Kovac SH, Spettell C, Westfall A, Weissman N, Wilkie S, **Saag KG**: Adverse Events Associated with Chronic Glucocorticoid Use among 2446 Adults. *Arthritis Rheum*, 50(S9):S301, 2004.
69. Curtis JR, Allison J, Gaffo A, Juarez L, Kovac SH, Olivieri J, Person S, Weissman N, **Saag KG**: A Group Randomized Controlled Trial to Improve NSAID-Related Safety Practices. *Arthritis Rheum*, 50(S9):S313, 2004.
70. Curtis JR, Allison J, Becker A, Casebeer L, George V, Kovac SH, Spettell CM, Westfall A, Weissman N, Wilkie S, **Saag KG**: Screening and Treatment of Glucocorticoid Induced Osteoporosis among 6517 Adults. *Arthritis Rheum*, 50(S9):S314, 2004.
71. Sampsel SL, Solomon DH, Brady T, Saleh K, Susman J, **Saag KG**, Renner P, Mardon R, Mierzejewski RM, MacLean CH: Measuring Pain and Functional Assessment in Adults with Arthritis. *Arthritis Rheum*, 50(S9):S319, 2004.
72. Sampsel SL, MacLean CH, Solomon DH, Susman J, **Saag KG**, Brady T, Saleh K, Renner P, Halim S, Mardon R: Measuring Quality in RA: DMARD Use. *Arthritis Rheum*, 50(S9):S319, 2004.
73. Sampsel SL, MacLean SH, Brady T, Saleh K, Solomon DH, Susman J, **Saag KG**, Mardon R, Renner P: Weight Loss and Exercise: Opportunities for Quality Improvement in Osteoarthritis. *Arthritis Rheum*, 50(S9):S320, 2004.
74. MacLean CH, Sampsel SL, **Saag KG**, Solomon DH, Brady T, Saleh K, Susman J, Renner P, Mardon R: Low Use of GI Prophylaxis with NSAIDs in High Risk Patients. *Arthritis Rheum*, 50(S9):S320, 2004.
75. Mikuls TR, Curtis J, Allison J, Hicks RW, **Saag KG**: Medication Errors with the use of Gout Related Therapies: Results from the United States Pharmacopeia MEDMARXsm Surveillance System. *Arthritis Rheum*, 50(S9):S339, 2004.
76. Bonnick S, **Saag K**, Kagan R, Kiel DP, Hochberg M, McClung M, Thompson D, Chen E, de Papp AE: 24 Months of OW Alendronate 70 mg Produces Greater Gains in BMD and Greater Reduction in Markers of Bone Turnover than OW Risedronate 35 mg with Similar Tolerability. Poster presented at the North American Menopause Society, September 30, 2005, San Diego, CA.

77. Abdolrasulnia M, Weichold N, Casebeer LL, Weissman NW, **Saag KG**, Allison J: Non-steroidal anti-inflammatory medication: do medical records agree with patient self report? *Pharmacoepidemiol Drug Saf* 14:S1, 2005.
78. Kovac SH, **Saag KG**, Curtis JR, Allison J: Association of dual use of Over-the-Counter and Prescription Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) with Health-Related Quality of Life. *Pharmacoepidemiol Drug Saf* 14:S11-S12, 2005.
79. Curtis JR, Becker A, Allison JJ, Casebeer L, Elkins M, George V, Kiefe C, Panjamapirom A, Santhanakrishnan R, Spettell C, Weissman N, Westfall AO, **Saag KG**: Recruiting physicians to an Internet-based quality improvement project: effectiveness of a targeted, multi-phase, incentive-based strategy. *Pharmacoepidemiol Drug Saf* 14:S95-S96, 2005.
80. Mudano AS, Bian J, Sampsel S, Elkins M, Briggs D, Neal A, Cope J, Gross T, McGunagle D, Graham J, Ferriter A, **Saag KG**: Characteristics of vertebroplasty patients: An analysis of claims data from a large not-for-profit healthcare insurer. *Pharmacoepidemiol Drug Saf* 14:S153-S154, 2005.
81. Curtis JR, Allison JJ, Westfall AO, Sampsel S, Kovac SH, **Saag KG**: Agreement and validation of self-report and pharmacy data for use of anti-osteoporotic medications. *Pharmacoepidemiol Drug Saf*, 14:S194-S195, 2005.
82. Curtis JR, Westfall AO, Allison JJ, Freeman A, **Saag KG**: A comparison of self-report and pharmacy data for current use of anti-osteoporotic medications. *J Bone Min Res*, 20(1 Suppl):S403, 2005.
83. Mudano AS, Bian J, Elkins M, Briggs D, Neal A, Cope J, Gross T, McGunagle D, Graham J, Ferriter A, **Saag KG**: Characteristics of vertebroplasty patients: an analysis of claims data from a large not-for-profit healthcare insurer. *J Bone Min Res*, 20(S1):S158, 2005.
84. Curtis JR, Bryant T, Kim Y, Scott D, Rousculp M, **Saag KG**: Osteoporosis treatment in the home health care setting: a window of opportunity? *J Bone Min Res*, 20(1 Suppl):S161, 2005.
85. Curtis JR, Westfall AO, Allison JJ, Kiefe CI, **Saag KG**: Persistence and adherence to alendronate and risedronate among chronic glucocorticoid users. *J Bone Min Res*, 20(1 Suppl):S279, 2005.
86. Curtis JR, Bryant T, Kim Y, Scott D, Rousculp M, **Saag KG**: Osteoporosis treatment in the home health care setting: a window of opportunity? *Arthritis Rheum*, 52(S9):S300, 2005.
87. Curtis JR, Westfall AO, Allison JJ, Freeman A, Kiefe CI, **Saag KG**: Persistence and adherence to alendronate and risedronate among chronic glucocorticoid users. *Arthritis Rheum*, 52(S9):S734-S735, 2005.
88. Curtis, JR, Amonkar MM, Mucha L, Barr CE, **Saag KG**: Persistence and Compliance With Daily and Weekly Bisphosphonate Therapy Over 3 Years. *Arthritis Rheum*, 54(S9):S84-S85, 2006.
89. Curtis JR, Barr CE, Baser O, Amonkar MM, **Saag KG**: Reduced Osteoporosis-Related Expenditures, Overall Healthcare Expenditures and Health Resource Utilization Observed for Women Adherent To Bisphosphonate Therapy. *Arthritis Rheum*, 54(S9):S85, 2006.

90. Curtis JR, Westfall AO, Allison JJ, Becker A, MacArthur M, Ockerhurst T, Stewart E, Weissman N, **Saag KG**: Challenges in Improving Quality of Osteoporosis Care for Long Term Glucocorticoid Users. *Arthritis Rheum*, 54(S9):S85, 2006.
91. McKendree-Smith NL, Bradley LA, **Saag KG**, Redden DT, Cannon R, Sotolongo A, Okonkwo R, McConley R: Ethnic Differences in Pain Anxiety and Severity: Toward Development of a Model of Ethnic Differences in Outcome Expectations and Preferences for Total Joint Arthroplasty (TJA). *Arthritis Rheum*, 54(S9):S103, 2006.
92. Curtis, JR, Niu J, Felson D, Hietpas J, Nair R, Nevitt M, Segal N, **Saag KG**, Sharma L, Torner J, Lewis C: Occupational Factors Associated with Symptomatic Radiographic Knee Osteoarthritis. *Arthritis Rheum*, 54(S9):S151, 2006.
93. Halpern R, **Saag KG**, Mody RR, Mikuls TR, Patel PA: Retrospective Claims Analysis of Gout Drug Utilization, Compliance and Associated Serum Urate Levels. *Arthritis Rheum*, 54 (S9):S332-S333, 2006.
94. Curtis JR, Reed J, Allison JJ, Moreland LW, **Saag KG**: How Adequately Do Propensity Scores Adjust for Confounding by Indication in the Absence of Disease-Specific Markers of Activity and Severity? *Arthritis Rheum*, 54(S9):S346, 2006.
95. Curtis JR, Martin C, **Saag KG**, Kramer J, Patkar N, Shatin D, Burgess M, Xie A, Allison JJ, Braun MM: Risk Factor of Heart Failure Among Younger Adults Exposed to Infliximab and Etanercept. *Arthritis Rheum*, 54(S9):S372, 2006.
96. Curtis JR, Patkar N, Xie A, Martin C, **Saag KG**: Implications of the Definition of an Infection When Assessing Risk Associated with Medications Use to Treat Rheumatoid Arthritis. *Arthritis Rheum*, 54(S9):S516-S517, 2006.
97. Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, **Saag KG**: Tumor Necrosis Factor- α Antagonists Increase the Risk of Hospitalization with a Bacterial Infection Among Rheumatoid Patients. *Arthritis Rheum*, 54(S9):S517, 2006.
98. Halpern R, Mikuls TR, **Saag KG**, Mody RR, Patel PA: Assessment of Quality of Care in Gout Using Claims Data. *Arthritis Rheum*, 54(S9):S700, 2006.
99. Fry RB, **Saag KG**, Curtis JR, Ray M, Allison JJ: Racial Disparities in NSAID-Related Risk Awareness and Communication. *Arthritis Rheum*, 54(S9):S826, 2006.
100. Bian J, Mudano A, Allison J, Briggs D, Cope J, Curtis J, Elkins J, Gross T, Kim Y, McGunagle D, Nair R, Xie A, **Saag KG**: Vertebroplasty/Kyphoplasty Increases the Risk of Secondary Vertebral Compression Fractures. *J Bone Min Res*, 21(1 Suppl):S105, 2006.
101. Colon-Emeric CS, **Saag K**, Levine D, Oliver K, Alison J, Xie A, House P, Schenck A, Gorospe J, Canady M, Curtis J, Weismann N, Fermazin M, Lyles KW: Prevalence and Predicators of Osteoporosis Treatment in Nursing Home Residents with Known Osteoporosis or Recent Fracture. *J Bone Min Res*, 21(1 Suppl):S404, 2006.

102. Greenspan S, Sebba A, **Saag K**, Thompson D, Rosenberg E, Chen E, de Papp A: Early Reduction in Bone Turnover Markers Are Associated with 24-Month Bone Mineral Density Response and Non-Response in the FOSAMAX ACTONEL Comparison Trial (FACT). *J Bone Min Res*, 21(1 Suppl):S415, 2006.
103. Luckey M, Bilezikian JP, Lindsay R, **Saag K**, Recknor C, Cahall D, Adachi R, Hodsmen A, Miller P: Impact of Prior Bisphosphonate Therapy on the Anabolic Effects of Teriparatide: Baseline Data for Subjects Enrolled in the OPTAMISE Study. *J Bone Min Res*, 21(1 Suppl):S416, 2006.
104. Stoch SA, Verbruggen V, Giezek H, Maragoto A, **Saag K**, Schnizer T: Effect of Alendronate Once Weekly on Bone Mineral Density in Patients with Glucocorticoid-Induced Bone Loss. *J Bone Min Res*, 21(1 Suppl):S418-S419, 2006.
105. Curtis JR, Westfall AO, Allison JJ, Becker A, MacArthur M, Ockerhausen T, Stewart E, Weissman N, **Saag KG**: Improving Quality of Osteoporosis Care for Long Term Glucocorticoid Users. *J Bone Min Res*, 21 (1 Suppl):S420, 2006.
106. Curtis JR, Amonkar MM, Mucha L, Barr CE, **Saag KG**: Osteoporotic Women Adherent to Bisphosphonate Therapy Have reduced Osteoporosis-Related and Total healthcare Costs. *J Bone Min Res*, 21(1 Suppl):S286, 2006.
107. Curtis JR, Amonkar MM, Baser O, Barr CE, **Saag KG**: Adherence to Bisphosphonate Therapy Results in Reduced Osteoporosis-Related Healthcare Utilization. *J Bone Min Res*, 21(1 Suppl):S287, 2006.
108. Hoes JN, Jacobs WG, Boers M, Boumpas D, Buttgerit F, Caeyers N, Choy EH, Cutolo M, Da Silva JA, Esselens GH, Guillevin L, Kirwan JR, Rovinsky J, Russell AS, Saag KG, Svensson B, Westovens R, Zeidler H, Bijlsma JW: EULAR evidence based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. *Ann Rheum Dis*. Published Online First: 27 July 2007.
109. Bian J, Mudano A, Allison J, Briggs D, Cope J, Curtis J, Elkins M, Gross T, Kim Y, McGunagle D, Nair R, Xie A, Saag KG. Vertebroplasty/Kyphoplasty Increases the Risk of Secondary Vertebral Compression Fractures. *Journal of Bone and Mineral Research* 2006; 21:S105.
110. MacLean CH, Pencharz JN, **Saag KG**: Quality indicators for the care of osteoarthritis in vulnerable elders. *J AM Geriatr Soc* 2007; 55 Suppl 2:S383-91.

Reviews and Editorials:

1. **Saag KG**, and Golbus J: Thromboangiitis Obliterans: A Clinical Update. *IM-Internal Medicine for the Specialist*, 1988; 9(11):93-104.
2. **Saag KG**, and Naides SJ: Practical Management for Suspected Viral Arthritis. *Contemporary Internal Medicine*, 1993; 5(5):35-49.
3. **Saag KG**, and Cowdery J: Nonsteroidal, Anti-inflammatory Drugs: Balancing Benefits and Risks. *Spine*, 1994;19:1530-1534.
4. **Saag KG**: Low Dose Corticosteroid Therapy in Rheumatoid Arthritis: Balancing the Evidence. *American Journal of Medicine*, 1997;(Suppl 6A), 103:31S-39S.

5. Karplus T, **Saag KG**: Do NSAIDs Have a Beneficial or Detrimental Effect on Cognitive Function? *Drug Safety*, 1998;19(6):427-433.
6. **Saag KG**: The Epidemiology of Steroid-Induced Osteoporosis: Concepts and Controversies. *J of Clin Rheumatol*, 1999;5:S3-9.
7. **Saag KG**: Osteoporosis in Rheumatoid Arthritis: the role of glucocorticoids, *Rheumatoid Arthritis Index & Reviews*. 1999; 2:3-5.
8. Criswell LC, **Saag KG**, Sems KM, Welch V, Shea B, Wells G, Suarez-Almazor ME: Rheumatoid Arthritis (RA) Moderate-Term Low Dose Corticosteroids for Rheumatoid Arthritis (Cochrane Review). In *The Cochrane Library*, Issue 1, 1999. Oxford: Update Software.
9. **Saag KG**: New Drug Profile on Rofecoxib (Commentary). *Drugs*, 1999;58:506-7.
10. Mikuls T, **Saag KG**: Comorbidity in Rheumatoid Arthritis. *Rheum Dis Clin North Am*. 2001; 27:283-303.
11. **Saag KG**: Point/Counterpoint: Con: Resolved: Low-dose glucocorticoids are neither safe nor effective for the long-term treatment of rheumatoid arthritis. *Arth Care Res*. 2001; 45:468-471.
12. **Saag KG**: Glucocorticoid use in rheumatoid arthritis. *Current Rheumatology Reports*. 2002; 4(3):218-25.
13. Misischia R, **Saag KG**: Glucocorticoid therapy for arthritis: Overcoming the problems. *J Musculoskel Med*. 2002; 19:96-109.
14. **Saag KG**: Metabolic bone disease (Editorial Overview) *Curr Opin Rheumatol*. 2002; 14:404-05.
15. **Saag KG**, Pisu M: Balancing bones and bucks among new glucocorticoid users (Editorial), *J Rheumatol*. 2003; 30:1-3.
16. Bajaj B and **Saag KG**: Osteoporosis: Evaluation and treatment. *Curr Womens Health Rep*, 2003;3:418-424.
17. **Saag KG**: Glucocorticoid-induced osteoporosis. *Endocrinol Metab Clin N Am*, 2003;32:135-157.
18. Kirwan J, Heigberg T, Hewlett S, Hughes R, Kvien T, Ahlmen M, Boers M, Minnock P, **Saag K**, Shea B, Suarez-Almazor M, Taal E: Outcomes from the patient perspective workshop at OMERACT 6. *J Rheumatol*, 2003; 30:868-72.
19. **Saag KG**: OMERACT 6 brings new perspectives on musculoskeletal research. (Editorial), *J Rheumatol*, 2003; 30:639-41.
20. Curtis J, **Saag KG**: 20 clinical pearls: use of corticosteroids in RA. *J Musculoskel Med*. 2003; 20(9):425-429.
21. Curtis JR, **Saag KG**: Evaluating and improving the quality of care in rheumatic disease. *Expert Rev Pharmacoeconomics Outcomes Res*. 2004; 44(4):429-439.

22. **Saag KG:** Prevention of glucocorticoid-induced osteoporosis (CME). *Southern Med J.* 2004; 97(6):555-558.
23. Townsend HB and **Saag KG:** Glucocorticoid use in rheumatoid arthritis: Benefits, mechanisms, and risks. *Clin Exp Rheumatol* 22(Suppl. 35):S77-S82, 2004.
24. Bijlsma JWJ, **Saag KG**, Buttgerit F, da Silva JAP: Developments in glucocorticoid therapy. *Rheum Dis Clin North Amer.* 2005; 31(1):1-17.
25. Buttgerit F, **Saag KG**, Cutolo M, da Silva JAP, Bijlsma JWJ: The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis. *Scand J Rheumatol.* 2005; 34:14-21.
26. **Saag KG**, Mikuls TR: Recent Advances in the Epidemiology of Gout, *Curr Rheum Reports.* 2005; 7:235-41.
27. Mikuls, TR, **Saag KG:** Gout Treatment: what is the evidence base and how do we determine and promote optimized clinical care? *Curr Rheum Reports.* 2005; 7:242-9.
28. Schumacher HR, Edwards LN, Perez-Ruiz F, Becker M, Chen LX, Furst DE, Joseph-Ridge N, Schlesinger N, Horowitz Z, **Saag K**, Boice JA, and Yamanaka H: Outcome Measures for Acute and Chronic Gout *J Rheumatol.* 2005; 32:2452-5.
29. Mikuls, TR, **Saag KG:** The Epidemiology of Gout. *Current Opinions in Rheum.* 2006; 18:199-203.
30. da Silva, JAP, Jacobs JWJ, Kirwan JR, Boers M, **Saag K**, Inês LBS, de Koning EJP, Buttgerit F, Cutolo M, Capell H, Rau R, Bijlsma JWJ: Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. *Ann Rheum Dis.* 2006; 65(3):285-93.
31. Allison JR, **Saag KG** (ed). Unbalanced Regulation of Over-the-Counter Analgesics: The Lesser of Two Evils?, *Pharmacoepi Drug Safety.* 2006;15:410-411
32. Nair R, **Saag KG:** The use of low-dose glucocorticoids for the treatment of early rheumatoid arthritis: what can we learn about bone effects of glucocorticoids from randomized controlled trials?, *Curr Rheumatol Rep.* 2006; 8(1):47-8.
33. Heffernan M, **Saag KG**, Robinson, JK, Callen JP: Prevention of osteoporosis associated with chronic glucocorticoid therapy, *JAMA.* 2006; 295(11):1300-3.
34. Gaffo A, **Saag KG**, Curtis J: Treatment in Rheumatoid Arthritis, *Am J Health System Pharmacy.* 2006; 63(24):2451-65.
35. Colon-Emeric CS, **Saag KG:** Osteoporosis Fractures in Older Adults. *Best Practice & Research Clinical Rheumatology.* 2006; 20(4):695-706.
36. Curtis JR, **Saag, KG:** Glucocorticoid Induced Osteoporosis, *Year in Akesson K, Adachi JD, Woolf AD (eds) The Year in Osteoporosis, Volume 2, Clinical Publishing, Oxford, UK, 2006*

37. Teng GG, Nair R, **Saag KG**: Pathophysiology, Clinical Presentation and Treatment of Gout, *Drugs*. 2006; 66(12):1547-63.
38. Chaimnuay S, **Saag KG**: Post menopausal Osteoporosis. What have we learned since the introduction of bisphosphonates? *Rev Endocr Metab Disord*. 2006; 7(1-2):101-12.
39. Palonen K, **Saag KG**: Improving the quality of clinical care for patients with osteoporosis, *Expert Review of Pharmacoeconomics & Outcomes Research*. 2006; 6(6): 641-5.
40. Chaiamnuay S, Saag KG: Postmenopausal osteoporosis. What have we learned since the introduction of bisphosphonates? *Rev Endocr Metab Disord*. 2006; 7(1-2):101-12.
41. Colon-Emeric CS, Saag KG: Osteoporotic fractures in older adults. *Best Pract Res Clin Rheumatol*. 2006; 20(4):695-706.
42. Chatham WW, Saag, KG: Is febuxostat a more effective treatment for hyperuricemia and gout than allopurinol? *Nat Clin Pract Rheumatol*. 2006; 2(5):240-1.
43. Curtis JR, **Saag KG**: Prevention and Treatment of Glucocorticoid-induced Osteoporosis. *Curr Osteoporos Rep*. 2007; 5(1):14-21.
44. Teng GG, Patkar N, **Saag KG**: Ibandronate injections in postmenopausal women with osteoporosis. *Current Rheumatology Reports*. 2007; 9(1):47; discussion 48-9.
45. Teng GG, Patkar N, **Saag KG**: Denosumab in postmenopausal women with low bone mineral density. *Current Rheumatology Reports*. 2007; 9(1):48; discussion 48-9.
46. **Saag KG**: Mend the Mind, but Mind the Bones!: Balancing Benefits and Potential Skeletal Risks of Serotonin Reuptake Inhibitors" has been published online in *Archives of Internal Medicine*. *Arch Intern Med*. 2007;167:1231-1232.
47. Curtis JR, **Saag KG**: Prevention and treatment of glucocorticoid-induced osteoporosis. *Curr Osteoporos Rep*. 2007; 5(1):14-21.
48. **Saag KG**, Choi H: Epidemiology, Risk Factors, and Lifestyle Modifications for Gout. *Arthritis Res Ther*, 2006;8 Suppl 1:S2.
49. Gaffo A, **Saag KG**: Treatment of acute gout-like arthritis in an emergency setting: prednisolone versus indomethacin, *Nat Clin Pract Rheumatol*, 2007 Nov; 3(11):604-5.
50. **Saag KG**, Pincus T: Introduction, 2007 Nov-Dec; 25(6) Suppl 47:S1-2.
51. Warriner, A, Curtis JR, **Saag, KG**: Challenges in defining and improving osteoporosis quality of care, *Clin and Exp Rheum*, 2007 Nov-Dec; 25(6) Suppl 47:S142-145.
52. Palonen K, **Saag KG**: Improving Clinical Care for Patients with Rheumatoid Arthritis, *Expert Review of Pharmacoeconomics & Outcomes Research*. In press.
53. Cafardi J, **Saag KG**: Effect of reproductive factors on the development of rheumatoid arthritis, *Women's Health*. In press.

Miscellaneous and Electronic Media:

1. Presentation: Workshop on the Problem Resident, "The Case of Dr. Westin." The Association of Program Directors in Internal Medicine, National Spring Meeting, 1990.
2. **Saag KG** (editor) Slide Set: Glucocorticoid-Induced Osteoporosis, 1999.
3. Website Improving Quality of Care for Glucocorticoid-induced Osteoporosis:
<http://www.certs.cme.uab.edu/>
4. Website Secondary Prevention of Osteoporosis: <http://www.spof.cme.uab.edu/>
5. Teng GG, Saag KG, "Diagnosis and Management of Acute and Chronic Gout" in Medscape
6. Saag KG, Curtis JR, ACR Hotline on Zoledronic Acid:
<http://www.rheumatology.org/publications/hotline/1007ZoledronicAcid.asp>.
hotline@rheumatology.org.

Manuscripts Submitted or In Preparation:

1. Kovac SH, **Saag KG**, Curtis JR, Allison J, Association of health-related quality of life with dual use of prescription and over-the counter non-steroidal anti-inflammatory drugs, submitted.
2. Stoch SA, **Saag KG**, Greenwald M, Sebba AI, Cohen S, Verbruggen N, Giezek H, Maragoto A, West J, Schnitzer TJ, Prevention and treatment of glucocorticoid-induced bone loss with once-weekly oral alendronate 70 mg: a 12-month randomized, placebo-controlled clinical trial, submitted.
3. _____, in preparation.
4. Curtis JR, **Saag KG**, Patkar N, Xi J, Martin C, Drug-Specific and Time-Dependent Risks of Bacterial Infections Rheumatoid Arthritis Patients Exposed to TNF-alpha, Antagonists, in press.
5. Warriner A, Curtis JR, **Saag KG**. Opportunities and Challenges in Improving Care in Osteoporosis. Clinical and Experimental Rheumatology, in press.
6. McDonough A, Curtis JR, Saag KG. The Epidemiology of glucocorticoid Associated Adverse Events. Current Opinion in Rheumatology, in press.